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  ABSTRACT 
Structural and Biochemical Characterizations of the Symplekin-Ssu72-CTD Complex in Pre-
mRNA 3’ end Processing 
Kehui Xiang 
 
RNA polymerase II (RNAP II) transcribes essentially all messenger RNAs (mRNAs) in 
eukaryotes. The C-terminal domain (CTD) of its largest subunit contains consensus heptad 
repeats Y1S2P3T4S5P6S7. Dynamic post-translational modifications of the CTD regulate RNAP II 
transcriptional activity and also facilitate transcription-coupled RNA processing events. One 
important mark is phosphorylation at Ser5 position, whose level peaks during transcription 
initiation but gradually diminishes toward the 3’ end of genes. Ssu72 is a known CTD pSer5 
phosphatase. Recent studies identified a binding partner of Ssu72, symplekin, which is an 
essential scaffold protein in pre-mRNA 3’ end processing. Little is known about the molecular 
function of symplekin and neither do we understand how the symplekin-Ssu72 interaction 
couples pre-mRNA 3’ processing to transcription.   
We first determined the crystal structure of the symplekin-Ssu72-CTD phosphopeptide 
complex. The N-terminal domain of symplekin embraces Ssu72 with its HEAT-repeat motif, 
serving as a typical molecular scaffold. Strikingly, the CTD phosphopeptide bound to the active 
site of Ssu72 has the peptide bond between pSer5 and Pro6 in the cis configuration, distinct from 
all known CTD conformations, which were exclusively in trans. While it was generally believed 
that only the trans peptide bond is recognized by proline-directed serine/threonine phosphatases 
or kinases, our discovery demonstrates for the first time that Ssu72 targets the energetically less-
favorable cis peptide bond. In addition, we found that the binding of symplekin and also the 
	  presence of a proline cis-trans isomerase can stimulate the phosphatase activity of Ssu72 in vitro. 
The symplekin-Ssu72 interaction as well as the catalytic activity of Ssu72 is required in our 
transcription-coupled polyadenylation assay. Overall, our study has important implications for 
the regulation of RNAP II transcription by cis-trans isomerization of the CTD and will help us 
understand how CTD modifications influence the recruitment of pre-mRNA 3’ end processing 
factors in a transcription-coupled manner.  
Recent studies showed that Ssu72 is also a phosphatase of CTD pSer7, which is involved 
in small nuclear RNA transcription and 3’ end processing. However, a pSer7 phosphatase 
activity appears to be inconsistent with our structure because pSer7 is followed by Tyr1’ of the 
next repeat rather than a proline, and it is unlikely for the pSer7-Tyr1’ peptide bond to be in cis 
configuration. To solve this conundrum, we determined the crystal structure of the pSer7 CTD 
peptide bound to Ssu72. Surprisingly, the backbone of the pSer7 CTD runs in an opposite 
direction compared with the pSer5 CTD, allowing a trans pSer7-Pro6 peptide bond to be 
accommodated in the active site. However, Ssu72 has a much lower affinity for pSer7 than pSer5 
and several structural features are detrimental for the catalytic activity towards pSer7. Consistent 
with these observations, our in vitro assays showed that the dephosphorylation of pSer7 by 
Ssu72 is ~4000-fold lower than that of pSer5. This further characterization of Ssu72 not only 
presents the first phosphatase in the literature that recognizes peptide substrates in both 
directions but also provides a more comprehensive understanding on CTD regulation by 
phosphatases from a structural perspective.  
Another protein, Rtr1, was recently suggested to function as a pSer5 phosphatase in a 
zinc-dependent fashion, separately or redundantly with Ssu72. We solved the crystal structure of 
Rtr1 and discovered a new type of zinc finger with no close structural homologs. Unexpectedly, 
	  Rtr1 does not present any evidence of an active site and it lacks detectable phosphatase activity 
in all our assays. We believe that, based on our results, Rtr1 does not have catalytic ability but 
instead indirectly regulate the phosphorylation state of the CTD.  
In summary, our studies on the symplein-Ssu72-CTD complex as well as Rtr1 have 
revealed several novel structural features that are essential for the CTD regulation at the atomic 
level. These results will also shed light on understanding the mechanism by which RNAP II 
transcription and RNA processing are coupled. 
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Preface 
This thesis is divided into five chapters. Chapter I reviews current knowledge of pre-
mRNA 3’ end processing from a structural perspective. Chapter II is a research article about 
structural studies of the symplekin-Ssu72-CTD phosphopeptide complex, provided in the 
original form published in Nature.  Chapter III is a research article that describes extended 
findings of Chapter II, also provided in the original form published in Genes Development. 
Chapter IV is a brief communication research article about structural and biochemical studies of 
Rtr1, in the original form published in Nature Communications. Chapter V summarizes our 




















The central dogma dictates that RNA serves to deliver genetic information from DNA to 
protein. In eukaryotic cells, messenger RNA (mRNA) is transcribed by RNA polymerase II 
(RNAP II) and nascent mRNAs, termed pre-mRNAs, undergo extensive modifications to 
become mature mRNAs that are subsequently exported out of the nucleus and translated into 
proteins. The modifications, including 5’ end capping, intron splicing and 3’ end processing, 
frequently happen co-transcriptionally and all contribute to ensure proper and efficient gene 
expression, transcript and genome stability as well as accurate translation and mRNA turnover 
(Bentley, 2002; Hirose and Manley, 2000; Li and Manley, 2006; Moore and Proudfoot, 2009; 
Proudfoot et al., 2002).   
3’ end processing of most pre-mRNAs involves a two-step reaction: an endonuclease 
cleaves the pre-mRNA and a poly (A) polymerase synthesizes a poly adenosine tail on the 
cleaved upstream product. The only known exceptions are metazoan histone pre-mRNAs, which 
are cleaved but not polyadenylated. The seemingly simple process involves intricate cis elements 
on the transcript and a massive and complex machinery consisting of more than 20 protein 
polypeptides in yeast (Zhao et al., 1999a) and as many as 80 in human cells (Shi et al., 2009). 
Pre-mRNA 3’ end processing is critical for many cellular events, from upstream coupled to 
transcription and splicing, and downstream to mRNA export, stability, translation and even 
decay (Mandel et al., 2008; Moore and Proudfoot, 2009). Defects in 3’ end processing can have 
catastrophic consequences for the cell and have been associated with a variety of human diseases 
(Danckwardt et al., 2008; Zhao et al., 1999a). Moreover, 3’ end processing can serve as a means 
for gene expression regulation through alternative polyadenylation (APA; Di Giammartino et al., 
2011; Tian and Manley, 2013). Recently, several genome-wide studies have shown that APA, 
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which involves use of different cleavage sites in the pre-mRNAs, is widely utilized in 
modulating mRNA transcript levels in diverse cell types and development stages, such as tumor 
cells, lymphocytes, iPS cells and embryogenesis (Ji and Tian, 2009; Ji et al., 2009; Mayr and 
Bartel, 2009; Sandberg et al., 2008). The general mechanisms governing APA are still largely 
unknown, and fully deciphering these will require detailed knowledge of pre-mRNA 3’ end 
processing at the molecular level.  
Early characterizations of mRNA 3’ end formation focused on genetic and biochemical 
studies, using a combination of in vivo and in vitro approaches. Sub-complexes, protein binding 
partners and individual factors were dissected layer by layer to unravel the complexity of the 
process (Colgan and Manley, 1997; Proudfoot, 2011; Zhao et al., 1999a). In the past decade, 
structural studies have thrived and played a major role in helping us interpret the molecular 
assembly and function of this machinery (Mandel et al., 2008; Yang and Doublié, 2011). From 
single protein to protein-protein complex, protein-RNA complex, and the entire assembly, the 
ultimate goal is to delineate the structural blueprint of the whole pre-mRNA 3’ end processing 
machinery with details at atomic resolution, not only mapping associations within the machinery 
and probing connections to other coupled nuclear events, but also understanding how the 
machinery operates and how it is regulated. In this review, we will summarize protein factors 
involved in pre-mRNA 3’ end processing, with emphasis on structural information and protein 
interaction networks, and how they translate into knowledge about the mechanistic function of 
the process. While both mammalian and yeast systems have been extensively studied as models 
in the past, we will primarily focus on the mammalian pre-mRNA 3’ end processing complex 




Pre-mRNA cis elements 
For 3’ end processing to occur at the correct place, pre-mRNAs need to contain 
conserved cis elements embedded in the primary sequence with defined information to guide the 
protein factors. The cleavage site has no apparent consensus, though it is often proceeded by a 
CA dinucleotide (Sheets et al., 1990). Accurate positioning of the 3’ end processing complex 
requires a combination of upstream and downstream cis elements. The AAUAAA hexamer 
polyadenylation signal (PAS) was the first element identified in playing such a role (Proudfoot 
and Brownlee, 1976). The PAS is highly conserved in mammalian mRNAs (Beaudoing et al., 
2000; Proudfoot, 1991; Tian et al., 2005). It is located between 10 to 35 nucleotides upstream of 
the cleavage site (Chen et al., 1995; Fitzgerald and Shenk, 1981; Hu et al., 2005) and is bound by 
the 3’ end processing factor CPSF (Bardwell et al., 1991; Bienroth et al., 1991; Gilmartin and 
Nevins, 1991; Murthy and Manley, 1992). A few other close sequence variants of the PAS have 
also been recognized, such as AUUAAA, UAUAAA, AGUAAA and UAUAAA (Beaudoing et 
al., 2000). Together they are responsible for directing more than 95% of polyadenylation in 
human mRNAs (Tian et al., 2005).  
A second major positioning cis element exists downstream of the cleavage site, generally 
within 30 nucleotides (MacDonald et al., 1994). Both the sequence and the location are less 
conserved compared with the PAS. The downstream element (DSE) was initially described as a 
single element with two forms, GU-rich (Hart et al., 1985; McLauchlan et al., 1985) and U-rich 
(Chou et al., 1994; Gil and Proudfoot, 1987). Subsequent computational analyses attributed them 
to two independent DSEs, which have distinct prevalence across eukaryotic species (Hu et al., 
2005; Salisbury et al., 2006). While the GU-rich DSE peaks at around 10 nucleotides 3’ end to 
the cleavage site, the U-rich DSE has a preferred position 15 nucleotides further downstream (Hu 
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et al., 2005; Salisbury et al., 2006). Both DSEs are likely recognized directly by the 3’ end 
processing factor CstF (Beyer et al., 1997; Deka et al., 2005; Pérez Cañadillas and Varani, 2003; 
Takagaki and Manley, 1997). 
Multiple UGUA consensus sequences can be located within 40-100 nucleotides upstream 
of many cleavage sites (Hu et al., 2005).  They provide a specific binding site for the essential 3’ 
end processing factor CFI (Venkataraman et al., 2005; Yang et al., 2010). The UGUA elements 
also serve as the primary sequence determinant for polyadenylation in some mRNAs that lack 
the PAS (Venkataraman et al., 2005). A tripartite mechanism has been proposed in that the PAS, 
the DSEs and the UGUA elements act cooperatively in directing poly(A) site recognition 
(Venkataraman et al., 2005; Yang and Doublié, 2011).  
Besides the core components, some auxiliary cis elements have also been identified 
computationally and experimentally, most of which play regulatory roles (Millevoi and Vagner, 
2010). Two U-rich elements can be located in the regions flanking the PAS (Hu et al., 2005). 
One precedes the cleavage site by 40-100 nucleotides while the other immediately follows the 
PAS, by an average of 5 nucleotides, both of which have been observed in many mRNAs (Levitt 
et al., 1989; Wilusz and Shenk, 1988). In addition, G-rich and C-rich elements were found either 
upstream or downstream but relatively distant from the cleavage site (Hu et al., 2005). Some of 
them can stimulate polyadenylation (Bagga et al., 1995; Yonaha and Proudfoot, 2000) but others 
have no functional role reported.  
In yeast, mRNAs have a distinct primary structure in poly(A) definition (see reviews 
Mandel et al., 2008; Zhao et al., 1999a). The cleavage site usually follows a pyrimidine and a 
stretch of adenosines (Heidmann et al., 1994), the position of which is defined by an A-rich 
positioning element (PE) located 10-30 nucleotides upstream (Guo and Sherman, 1995). PE has 
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a similar sequence consensus to PAS but assumes a less essential role. Strangely, PE is not 
recognized by the yeast counterpart of CPSF but rather the CstF homolog CFIA. Another UA-
rich efficiency element (EE) is present further upstream. It is bound by CFIB and is mainly 
responsible for improving processing efficiency. Moreover, some conserved upstream and 
downstream U-rich elements have also been identified to synergistically enhance the cleavage 
and polyadenylation (Dichtl and Keller, 2001; Graber et al., 1999). However, protein factors that 
associate with these cis elements remain elusive.  
 
Trans-acting protein factors 
Mammalian pre-mRNA 3’ end processing can be reconstituted in vitro with exogenous 
RNA substrates and cell nuclear extracts (Moore and Sharp, 1985). This assay system provided a 
powerful means to identify active trans-acting components involved in the cleavage and 
polyadenylation. Early studies were devoted to biochemical fractionation and characterization. 
Five major factors were identified and separated during a series of purification steps:  Cleavage 
and Polyadenylation Specificity Factor (CPSF), Cleavage stimulation Factor (CstF), Cleavage 
Factor I (CFI), Cleavage Factor II (CFII) and Poly(A) Polymerase (PAP) (Christofori and Keller, 
1988; Gilmartin and Nevins, 1989; Takagaki et al., 1988, 1989). All these factors, with the 
exception of PAP, are multi-subunit protein complexes. They constitute a mega-dalton 
machinery acting on a seemingly simple two-step enzymatic reaction. While polyadenylation 
only requires CPSF and PAP, all factors are indispensible for efficient cleavage of the pre-
mRNA.  
Some other essential members of the 3’ end processing machinery were discovered 
subsequently, including poly(A) binding protein PABPN1, the RNAP II largest subunit C-
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terminal domain (CTD) and symplekin (Wahle, 1991a; McCracken et al., 1997; Hirose and 
Manley, 1998; Takagaki and Manley, 2000). A recent systematic proteomic study revealed even 
more proteins that are associated with the 3’ end processing complex (Shi et al., 2009). Some of 
them are bona fide components, some serve regulatory roles and others may assist in coupling to 
other processes.  
Compared to the mammalian 3’ end processing complex, the yeast machinery is 
assembled in a different way. Proteins are found in 3 main factors: Cleavage and 
Polyadenylation Factor (CPF), Cleavage Factor IA (CFIA) and Cleavage Factor IB (CFIB) (see 
reviews Mandel et al., 2008; Zhao et al., 1999a). The yeast processing complex contains several 
components that do not exist in the mammalian system and it also lacks some proteins in the 
machinery of mammals. Despite the evolutionary divergence, evident conservation and similarity 
still prevail at the protein level. For example, CPF contains all the homologous proteins from 
CPSF, and CFIA are composed of members that share high homology with those in CstF and 
CFII.  
In the following sections, we will describe each mammalian pre-mRNA 3’ end 
processing factor and also their respective yeast homologs in more detail. A list of protein-
protein interactions that have been studied is provided in Table 1. The protein structures that 
have been reported are summarized in Table 2. 
 
Cleavage and Polyadenylation Specificity Factor (CPSF) 
CPSF defines the specificity of pre-mRNA 3’ end processing and is required for both 
cleavage and polyadenylation (Christofori and Keller, 1988; Gilmartin and Nevins, 1989; 
Takagaki et al., 1989). CPSF also plays important roles in transcription coupling, as it is 
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recruited by TFIID to the transcription initiation complex and then it accompanies RNAP II 
throughout the transcription process to the 3’ end (Dantonel et al., 1997). CPSF weakly 
recognizes the PAS, but the binding is enhanced by the presence of CstF (Bardwell et al., 1991; 
Bienroth et al., 1991; Gilmartin and Nevins, 1991; Murthy and Manley, 1992). Early 
purifications of CPSF revealed that it contained four polypeptides: CPSF-160, CPSF-100, CPSF-
73 and CPSF-30, all of which were named according to their estimated molecular weight on 
electrophoresis gels (Bienroth et al., 1991; Murthy and Manley, 1992). A later biochemical study 
identified a bona fide member, Fip1(Kaufmann et al., 2004), and more recently a sixth 
component of CPSF was proposed, WDR33 (Shi et al., 2009).   
The CPSF subunit that gained most attention recently is CPSF73, largely because it turns 
out to be the essential endonuclease for the cleavage reaction that researchers have been hunting 
for three decades (Dominski, 2010). The earliest clue came from a sequence analysis showing 
that CPSF-73 belongs to the metallo-β-lactamase (MβL) superfamily, whose members are 
mostly hydrolases dependent on metal ions (Callebaut et al., 2002). Yeast cells with mutations of 
the putative residues for zinc binding in Ysh1 (yeast homolog of CPSF-73) are lethal (Ryan et 
al., 2004). Furthermore, zinc chelators added into HeLa cell nuclear extract significantly reduced 
and even abolished 3’ end cleavage (Ryan et al., 2004). Despite all the evidence pointing at 
CPSF-73, the definitive piece didn’t arrive until the crystal structure of CPSF-73 was 
determined. 
The N-terminal region of CPSF-73 (residue 1-460) contains a canonical MβL domain 
with a four-layer αβ/βα sandwich (Figure 1). There are additional strands at the carboxy-terminal 
region of this domain, which are also present in CPSF-100 and RNaseZ, likely a unique 
characteristic for nucleases (Mandel et al., 2006a). A novel β-CASP domain featuring β strands 
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surrounded by α helices is inserted like a cassette into the MβL domain. In the active site, two 
zinc atoms are octahedrally coordinated to essential motifs within the MβL domain, similar to 
the binding mode in RNase Z but not other canonical MβLs (Li de la Sierra-Gallay et al., 2005; 
Mandel et al., 2006a). However, the active site is buried at the interface between the β-CASP 
domain and the MβL domain, whose access to the RNA substrate is severely restricted. This 
likely explains why the bacterially expressed N-terminal domain of CPSF-73 displayed minimal 
nuclease activity in vitro. Strikingly, calcium cation was able to activate this protein, through a 
mechanism that is not understood but was speculated to involve conformational changes 
triggered by the cation (Mandel et al., 2006a). 
In recent years, many bacterial and archaeal CPSF-73 homologs belonging to the β-
CASP family have been well studied and a handful of crystal structures have been determined, 
shedding light on the catalytic mechanism of CPSF-73 (Ishikawa et al., 2006; Li de la Sierra-
Gallay et al., 2008; Mir-Montazeri et al., 2011; Nishida et al., 2010; Silva et al., 2011) (Figure 
1B). Bacterial RNase J has a similar overall domain architecture as CPSF-73 (Figure 1A). The 
additional C-terminal region that was missing in the CPSF-73 structure is connected to the MβL 
domain through a long linker, indicating a certain degree of flexibility. Importantly, this C-
terminal domain mediates the dimerization of RNase J and is crucial for its nuclease activity (Li 
de la Sierra-Gallay et al., 2008).  Archaeal β-CASP proteins have extra KH motifs at the N-
terminus, which are responsible for RNA recognition (Figure 1A). They form dimers through 
their extreme C-terminal region within the MβL domain, unlike RNase J (Mir-Montazeri et al., 
2011; Nishida et al., 2010; Silva et al., 2011). Based on these studies, another question arises: 
Does CPSF-73 display a similar mechanism by which dimerization through the C-terminal 
domain is required to cleave the RNA? The structural information is not yet available, nor do we 
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know if CPSF-73 can self-associate, but the fact that full-length CPSF-73 purified from HEK293 
cells was not active (Kolev et al., 2008) suggests that CPSF-73 likely employs a different 
mechanism. In yeast, the C-terminal domain of Ysh1 is required for survival and both cleavage 
and polyadenylation (Zhelkovsky et al., 2006).  Other studies indicate that CPSF-73 makes direct 
contact with CPSF-100 and symplekin through the C-terminal domain (Dominski et al., 2005a; 
Zhelkovsky et al., 2006). It is therefore tempting to hypothesize that CPSF-73 and CPSF-100 (a 
sequence homolog of CPSF-73, see below) form a heterodimer to perform catalysis, or a third 
protein such as symplekin may be required to activate the nuclease activity of CPSF-73 
(Dominski, 2007, 2010). 
CPSF-73 is also involved in mammalian histone pre-mRNA 3’ end processing (Dominski 
et al., 2005b). UV-crosslinking experiments placed CPSF-73 in the vicinity of both the cleavage 
site and the downstream product in a U7 snRNP dependent manner, indicating CPSF-73 might 
be both an endonuclease and a 5’ to 3’ exonuclease in this case (Dominski et al., 2005b; Yang et 
al., 2009).  Exonuclease activity was not detected with the N-terminal domain of CPSF-73 
(Mandel et al., 2006a), though it has been observed with other β-CASP proteins (Dominski, 
2007; Phung et al., 2013). Whether CPSF-73 is a genuine 5’to 3’ exonuclease is still under 
debate, but if it is, other partners might be required for this activity (Dominski, 2010).  
Like CPSF-73, CPSF-100 also belongs to the β-CASP family and they share high 
sequence homology (Callebaut et al., 2002; Jenny et al., 1996) (Figure 1A). However, it lacks 
conserved motifs that are essential for catalytic activity and is thus considered to be inactive 
(Callebaut et al., 2002). The crystal structure of the N-terminal domain of yeast CPSF-100 
homolog (Ydh1) has been determined. The domain organization of CPSF-100 is very similar to 
CPSF-73 and other β-CASP proteins, but equivalent motifs critical for zinc binding are missing 
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in CPSF-100, making it incapable of catalysis (Mandel et al., 2006a). The β-CASP domain in 
CPSF-100 is noticeably larger than that in CPSF-73. A segment in this region containing almost 
200 residues was not observed in the structure, probably being proteolytically digested during 
crystallization (Mandel et al., 2006a, 2006b). All CPSF-100 proteins from different species have 
this highly hydrophilic region with variable length, but its biological significance is currently 
unknown.  
The exact function of CPSF-100 is not clear, but several studies have shown its 
importance in pre-mRNA 3’ end processing. In yeast, Ydh1 is indispensible for cell viability and 
its mutants have negative effects on cleavage and polyadenylation (Kyburz et al., 2003; Preker et 
al., 1997). Ydh1 can also be UV-crosslinked to the pre-mRNA in a cis-element dependent 
manner and it may make direct contact with select RNA substrates (Dichtl and Keller, 2001; 
Zhao et al., 1997). GST pull-down assays indicate that Ydh1 interacts with the RNAP II CTD 
and Pcf11, raising its potential role in transcription coupled pre-mRNA processing (Kyburz et 
al., 2003). CPSF-100 is tightly associated with CPSF-73, likely through their C-terminal domains 
(Dominski et al., 2005a). CPSF-73, CPSF-100 and symplekin constitute a core complex in both 
pre-mRNA and histone pre-mRNA 3’ end processing (Sullivan et al., 2009). These results 
indicate that CPSF-100 may play crucial regulatory roles in modulating the nuclease activity of 
CPSF-73 through direct interaction or by recruiting other factors. 
CPSF-30 is the smallest member in the CPSF complex. Earlier studies debated about 
whether it is part of CPSF, because it appeared less than stoichiometric in some preparations 
(Bienroth et al., 1991; Murthy and Manley, 1992) and its yeast homolog Yth1 did not appear to 
be in the same complex with other CPSF homologs (Zhao et al., 1997). Its identity was backed in 
later studies but its association with the rest members of CPSF seems weak (Jenny et al., 1994). 
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Despite this controversy, CPSF-30 is essential for cleavage and polyadenylation in both yeast 
and mammalian cells (Barabino et al., 1997, 2000).  
 
Figure 1. Cleavage and Polyadenylation Specificity Factor (CPSF). (A) Domain organization of human CPSF 
subunits and two CPSF-73 homologs. (B) Structural comparison between CPSF-73 (PDB ID: 2I7T (Mandel et al., 
2006a)) and its bacterial and archaeal homologs, RNase J (PDB ID: 3BK1 (Li de la Sierra-Gallay et al., 2008)) and 




CPSF-30 consists of five CCCH zinc finger motifs and a CCHC zinc knuckle motif at the 
C-terminus that is not present in Yth1 (Barabino et al., 1997) (Figure 1A). Structures of these 
motifs in other proteins have been determined and characterized in RNA recognition (D’Souza 
and Summers, 2004; Hudson et al., 2004), strongly indicating that CPSF-30 may bind to the pre-
mRNA. Indeed, CPSF-30 can be UV-crosslinked to RNA oligomers, with a preference for  
poly(U) sequences (Barabino et al., 1997; Jenny et al., 1994). Interestingly, a conserved U-rich 
element is often located next to the PAS (Hu et al., 2005), presenting a strong candidate for the 
CPSF-30 binding site in vivo. In yeast, Yth1 binds the pre-mRNA near the cleavage site 
(Barabino et al., 2000), and its RNA recognition ability can be impaired with the removal of 
either zinc finger motif 2 or 4 (Tacahashi et al., 2003).  
The zinc fingers in CPSF-30 are also responsible for making contacts with other factors 
involved in pre-mRNA 3’ end processing. In fact, it is not uncommon that zinc finger motifs can 
mediate protein-protein interactions (Gamsjaeger et al., 2007). In the case of Yth1, the integrity 
of zinc finger 4 is crucial for binding to Fip1 as well as Ysh1 (Barabino et al., 1997, 2000; 
Tacahashi et al., 2003).  These two interactions are aided respectively by the C-terminus and the 
N-terminus of Yth1 (Barabino et al., 2000; Tacahashi et al., 2003). Besides factors in the 
cleavage and polyadenylation complex, CPSF-30 was found to interact with the NS1A protein 
from influenza A virus, a mechanism employed by the virus to inhibit host pre-mRNA 3’ end 
processing (Nemeroff et al., 1998). The crystal structure of NS1A in complex with zinc finger 2 
and 3 of CPSF-30 has been solved. The two zinc fingers show high structural similarity to other 
CCCH zinc finger proteins, in agreement with the proposed RNA recognition function (Das et al., 
2008). CPSF-30 also binds to the body of RNAP II, likely responsible for the association of 
CPSF and RNAP II during transcription elongation (Nag et al., 2007). 
	  	  
14 
The largest subunit, CPSF-160, can be UV-crosslinked to pre-mRNA in a PAS-
dependent manner (Gilmartin and Nevins, 1989; Keller et al., 1991). Purified recombinant 
CPSF-160 protein was shown to bind RNA selectively but the affinity for the AAUAAA 
sequence was lower than intact CPSF, indicating other factors in CPSF may help stabilize the 
interaction (Murthy and Manley, 1995).  The yeast homolog, Yhh1, is essential for both cleavage 
and polyadenylation (Dichtl et al., 2002).  
CPSF-160 is composed of tandem WD40 repeats clustered into 3 major β-propellers 
(Neuwald and Poleksic, 2000) (Figure 1A). Though no structural information is available, CPSF-
160 shares low sequence homology but similar domain architecture with DDB1, a scaffold 
protein for cullin-binding in E3 ubiquitination, whose structure has been well characterized in the 
literature (Angers et al., 2006; Li et al., 2006; Scrima et al., 2008). In fact, WD40 domain is one 
of the most abundant domains in eukaryotic proteomes and also the top protein interacting 
domain in human and yeast interactome databases (Stirnimann et al., 2010). Many β-propeller 
protein structures have been determined. They generally serve as scaffolds in protein-protein 
interactions (Stirnimann et al., 2010), but exceptions exist. For example, the WD40 domain of 
DDB2, a protein involved in DNA lesion repair, can recognize DNA (Scrima et al., 2008). This 
structural evidence explains the fact that CPSF-160 is involved in both protein-protein and 
protein-RNA interactions. In particular, CPSF-160 makes direct contacts with CstF-77 and 
interacts weakly with PAP (Murthy and Manley, 1995). The middle β-propeller domain of Yhh1 
binds RNA (Dichtl et al., 2002).  
CPSF-160 is also involved in transcription-coupled 3’ end processing. Yhh1 mutants 
gave rise to defects in transcription termination in yeast and Yhh1 interacts with phosphorylated 
RNAP II CTD in vitro and in vivo, though this interaction was not impaired in the mutants and 
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thus not the cause for the transcription termination defects (Dichtl et al., 2002). More 
importantly, CPSF-160 binds to several factors in TFIID, mainly accounting for CPSF being 
recruited to the RNAP II pre-initiation complex (Dantonel et al., 1997). 
Fip1 was identified more than a decade later than the above mentioned CPSF members, 
though its yeast homolog had been known for a long time. It was shown that Fip1 could stably 
associate with all other components of CPSF. Immuno-depletion of Fip1 impairs both cleavage 
and polyadenylation, which can be rescued by CPSF (Kaufmann et al., 2004). In contrast, yeast 
Fip1 mutants affect polyadenylation but not cleavage (Preker et al., 1995). Human Fip1 is almost 
twice as large as its yeast counterpart and has a C-terminal extension containing two extra 
domains (Kaufmann et al., 2004) (Figure 1A). The N-terminal regions of the two proteins share 
similar domain organization but have relatively low sequence conservation (Kaufmann et al., 
2004).  
Yeast Fip1 was originally discovered in a yeast two-hybrid screen for binding partners of 
Pap1 (Preker et al., 1995). Their strong interaction tethers Pap1 to other 3’ end processing factors 
to ensure specificity in polyadenylation (Preker et al., 1995). A fragment of Fip1 (residue 80-
105) has been co-crystallized with Pap1. In the complex structure, Fip1 binds to the C-terminal 
domain of Pap1, distant from the active site (Meinke et al., 2008). The binding of this peptide 
stabilizes Pap1, but it induces minimal structural changes and has little effect on the catalytic 
activity (Meinke et al., 2008). Mutations that disrupt this interaction cause lethality in yeast 
(Meinke et al., 2008). Interestingly, residues at the interface are not conserved in either Fip1 or 
Pap1 but the interaction between these two proteins has been observed across different 
eukaryotic species, including yeast, plants and human (Forbes et al., 2006; Meinke et al., 2008; 
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Preker et al., 1995). A more recent study showed that only the tethering but not the atomic details 
of these two proteins is essential for polyadenylation (Ezeokonkwo et al., 2011).   
Human Fip1 has been shown to bind multiple partners. Besides PAP, Fip1 also binds to 
CPSF-30, CPSF-160 as well as CstF-77. These interactions are mainly mediated by its N-
terminal region, which is homologous to its yeast counterpart, but the C-terminus may also play 
a role (Kaufmann et al., 2004). The C-terminal arginine-rich domain can also bind to RNA, 
particularly U-rich sequences (Kaufmann et al., 2004). This interaction likely mediates the Fip1-
dependent stimulation of PAP in specific polyadenylation in vitro, because removal of the 
potential binding sites on the pre-mRNA abolishes the stimulatory effect (Kaufmann et al., 
2004). In yeast, Fip1 inhibits Pap1 activity in non-specific polyadenylation, probably through a 
different mechanism due to its lack of the equivalent RNA binding domain (Helmling et al., 
2001).  In solution, Fip1 seems to be a largely disordered protein (Meinke et al., 2008), and its 
extended nature can provide scaffolding interactions with multiple proteins (Gunasekaran et al., 
2003).  
WDR33/WDC146 was proposed to be a bona fide CPSF component from a proteomic 
study (Shi et al., 2009). WDR33 is a 146kD protein that consists of an N-terminal WD40 
domain, a middle collagen-like domain and a C-terminal GPR (glycine-proline-arginine) domain 
(Ito et al., 2001) (Figure 1A). It migrates at a position very close to CPSF-160 on SDS-gels, 
probably explaining why it was missed in earlier studies (Shi et al., 2009). Subsequent 
biochemical characterizations indicate WDR33 co-elutes with all CPSF members during gel 
filtration and is essential for cleavage in vitro (Shi et al., 2009). However, the exact function of 
this protein is not known.  
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Pfs2, the yeast homolog of WDR33, is not only required for cell survival but also critical 
for both cleavage and polyadenylation (Ohnacker et al., 2000). Pfs2 has a smaller size and only 
contains the WD40 domain (Ohnacker et al., 2000). As mentioned above, WD40 repeats are 
commonly involved in protein-protein interactions and indeed Pfs2 binds to many protein factors 
in the pre-mRNA 3’ end processing complex, including Rna14, Ysh1, Fip1 (Ohnacker et al., 
2000) and Clp1 (Ghazy et al., 2012).  Additionally, an S. pombe Pfs2 mutant was shown to have 
defects in transcription termination, suggesting a potential role in transcription-coupled 
polyadenylation (Wang et al., 2005).  
 
Cleavage stimulation Factor (CstF) 
CstF was initially purified as a factor not required for polyadenylation but significantly 
enhanced the cleavage reaction (Takagaki et al., 1989). However, CstF is now considered 
essential, and the initial studies likely reflected residual CstF in other fractions. CstF activity 
reflects in part the cooperative binding of CPSF and CstF to the pre-mRNA (Gilmartin and 
Nevins, 1991; Wilusz et al., 1990), in which CstF recognizes the DSEs (MacDonald et al., 1994). 
Like CPSF, CstF also associates with RNAP II during transcription elongation and facilitates 
transcription-coupled 3’ end processing (McCracken et al., 1997). Three proteins were found in 
the CstF complex: CstF-77, CstF-64 and CstF-50 (Gilmartin and Nevins, 1991; Takagaki et al., 
1990).  
A computational analysis identified the N-terminal region of CstF-77 as a HAT (half a 
TPR) domain (Figure 2A), because the sequence bears similar repetitive patterns to the TPR 
motif but lacks some conserved residues (Preker and Keller, 1998). The TPR (tetratrico-peptide 
repeat) is a 34-amino acid motif adopting helix-turn structure, which generally serve as 
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interacting modules with other proteins or themselves (Zeytuni and Zarivach, 2012). The crystal 
structure of the HAT domain of CstF-77 has been determined, revealing an intrinsic dimeric 
association (Bai et al., 2007; Legrand et al., 2007) (Figure 2B). The HAT domain dimerizes into 
an elongated shape, with each made up of a HAT-N domain and a HAT-C domain in a 
perpendicular organization (Bai et al., 2007). The HAT-C domain not only mediates CstF 
dimerization (Bai et al., 2007) but also makes contacts with other proteins, such as CPSF-160 
(Bai et al., 2007) and CstF-50 (Takagaki and Manley, 2000). Subsequent biophysical and 
biochemical experiments confirmed the self-association of CstF-77, suggesting that the CstF 
complex assembles with two copies of each subunit (Bai et al., 2007). In fact, this is consistent 
with an earlier biochemical characterization (Takagaki and Manley, 2000) as well as genetic 
studies in flies (Benoit et al., 2002). Similar characteristics have also been observed in the fungal 
homolog of CstF-77, Rna14. The HAT domain of Rna14 from K. lactis dimerizes in mostly the 
same way as that of CstF-77, despite significant structural variations (Paulson and Tong, 2012). 
Disruption of this dimerization in yeast can severely impair both pre-mRNA cleavage and 
polyadenylation (Gordon et al., 2011).  
CstF-77 interacts with both CstF-50 and CstF-64, in a way that bridges them since the 
other two factors make no direct contacts (Takagaki and Manley, 1994, 2000). The C-terminal 
part of CstF-77 contains a proline-rich region which is required for the binding to CstF-64 (Bai et 
al., 2007; Hockert et al., 2010; Takagaki and Manley, 2000). This interaction is both sufficient 
and necessary for the nuclear localization of CstF-64 (Hockert et al., 2010; Ruepp et al., 2011a) 
and may also facilitate RNA recognition by CstF-64 (see below). In yeast, Rna14 and Rna15 
(CstF-64 homolog, see below) assemble through the same regions (Legrand et al., 2007; 
Moreno-Morcillo et al., 2011a; Paulson and Tong, 2012). With the dimerization of Rna14, they 
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constitute a α2β2 tetramer in the shape of kinked rod (Noble et al., 2004). The complex structure 
of Rna14 hinge domain and Rna15 C-terminal domain has been obtained alone (Moreno-
Morcillo et al., 2011a) and together with the HAT domain of Rna14 (Paulson and Tong, 2012) 
(Figure 2C). The two domains tether as an interlocked structure, through which they stabilize 
each other (Moreno-Morcillo et al., 2011a; Paulson and Tong, 2012). This formation requires 
cooperative folding between the two proteins and probably reflects their tight association in vivo 
(Moreno-Morcillo et al., 2011a). Additionally, there is a long linker connecting the HAT domain 
and the C-terminal domain of Rna14, making the two domains flexible and possibly functionally 
independent (Paulson and Tong, 2012).   
CstF-64 was the first protein in the pre-mRNA 3’ end processing machinery shown to 
UV-crosslink to the RNA (Wilusz and Shenk, 1988). This effect, later found to be independent 
of the PAS, can be attributed to an RNA Recognition Motif (RRM) at its N-terminus (Takagaki 
et al., 1992) (Figure 2A). Further investigation revealed that the RRM can specifically recognize 
the U-rich DSE (MacDonald et al., 1994) and it selects GU-rich sequences in vitro (Takagaki 
and Manley, 1997). The structure of the RRM has been determined. By comparative analysis 
with other RRM structures, a binding pocket was identified at the surface of the central β-sheet 
to accommodate UU dinucleotides, whose presence could enhance the RNA-RRM interaction 
appreciably (Pérez Cañadillas and Varani, 2003). It was believed that with fine-tuning of 
contacts outside this pocket, the RRM is able to modulate its preference for a wide selection of 
Gs and Us while still discriminating against other RNA sequences (Pérez Cañadillas and Varani, 
2003). This specific binding variability enables CstF-64 to recognize both U-rich and GU-rich 
DSEs. In fact, the two DSEs are in close distance (within 15 nucleotides) and might be bound by 
two copies of CstF-64 simultaneously, which are readily bridged by the long HAT domains of 
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CstF-77. This also supports the dimeric association of CstF, constructed around the CstF-77 
HAT domain dimer.  
The yeast homolog of CstF-64, Rna15, not only bears high sequence identity but also 
shares structural similarity in the RRM region. However, Rna15 also has some distinct 
characteristics. The RRM of Rna15 has a generally lower affinity for the RNA (Noble et al., 
2004) though it preferentially binds to U-rich or GU-rich consensus in vitro (Pancevac et al., 
2010; Takagaki and Manley, 1997). There are two RNA binding sites identified in the RRM 
structure of Rna15 (Pancevac et al., 2010) (Figure 2E). The primary site is located at a surface 
loop, whose interactions with the RNA are mediated by specific hydrogen bonding. Such a 
configuration would not form if A or C nucleotides were placed at the same location, largely 
explaining the specificity for GU-rich sequences (Pancevac et al., 2010). The second site is 
positioned at a canonical RRM-RNA contact region as in CstF-64 (Pancevac et al., 2010; Pérez 
Cañadillas and Varani, 2003). This interaction is facilitated predominantly by base-aromatic ring 
stacking and thus less specific. In a different scenario, with the presence of Rna14 or Hrp1 (a 
yeast CFI component that binds the EE, no mammalian homolog), the binding of the RRM of 
Rna15 to the RNA can be considerably enhanced and directed to the PE in yeast (Gross and 
Moore, 2001b; Noble et al., 2004). The structure of the Rna15-Hrp15-RNA complex gave a clear 
atomic view of how this recognition occurs (Figure 2F). The two RRMs of Hrp1 not only 
specifically recognize the UA-rich RNA sequence but also interacts with Rna15, which brings 
the RRM of Rna15 adjacent to the A-rich PE element (Leeper et al., 2010). As a result of the 
cooperative binding, Rna15 is able to attach to this sequence in a canonical manner through the 
less specific site. In fact, the two distinct RNA binding modes of Rna15 can be well suited in the 
context of the yeast CFI complex. Recent studies have shown that there are two copies of Rna15 
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but only one copy of Hrp1 (Barnwal et al., 2012; Gordon et al., 2011). It is possible that one 
Rna15 in complex with Hrp1 associates with the EE while the other Rna15 alone recognizes a 
not-so-far U-rich consensus upstream of the cleavage site (Dichtl and Keller, 2001; Graber et al., 
1999), with each involving different binding mechanisms (Leeper et al., 2010; Pancevac et al., 
2010).   
Following the RRM in CstF-64 is a hinge region that interacts with both CstF-77 and 
symplekin, in a mutually exclusive manner (Ruepp et al., 2011a; Takagaki and Manley, 2000, 
see below). The CstF-64-CstF-77 interaction is conserved between human and yeast. 
Interestingly, in the Rna14-Rna15 complex structure, the helix immediately preceding the hinge 
region from Rna15 displays high flexibility and can be locally unfolded (Moreno-Morcillo et al., 
2011a). A similar characteristic of the same helix was also observed in both CstF-64 and Rna15 
RRM structures (Pancevac et al., 2010; Pérez Cañadillas and Varani, 2003). This connecting 
helix maintains contacts with the central β-sheet of the RRM in a way that it blocks the RNA 
binding site (Pancevac et al., 2010; Pérez Cañadillas and Varani, 2003). Such a feature of the C-
terminal α-helix extension is not uncommon in a variety of RRM structures (Dominguez et al., 
2010; Nagai et al., 1990; Oubridge et al., 1994; Schellenberg et al., 2006; Selenko et al., 2003). It 
is likely that the partner association to the hinge region of CstF-64/Rna15 triggers unfolding of 
this helix, making the RRM accessible to RNA. In fact, it has been observed that the binding of 
Rna14 substantially boosts the Rna15-RNA interaction (Noble et al., 2004), which can be further 




Figure 2. Cleavage stimulation Factor (CstF). (A) Domain organization of human CstF subunits. (B) Crystal 
structure of the murine CstF-77 HAT domain (PDB ID: 2OOE (Bai et al., 2007)). (C) NMR structure of the Rna14 
C-terminal Rna15-binding domain in complex with the hinge region of Rna15 (PDB ID: 2L9B (Moreno-Morcillo et 
al., 2011a)).  (D) Crystal structure of the dimerization domain of CstF-50 (PDB ID: 2XZ2 (Moreno-Morcillo et al., 
2011b)). (E) Crystal structure of the RRM domain of Rna15 with RNA bound at primary and secondary sites (PDB 
ID: 2X1A, 2X1F (Pancevac et al., 2010)). (F) NMR structure of the RRM of Rna15, two RRMs of Hrp1 and RNA 
ternary complex (PDB ID: 2KM8 (Leeper et al., 2010)). 
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Compared to the first two domains, the remaining part of CstF-64 is less well studied. 
The domain at the very C-terminus of CstF-64 is highly conserved in eukaryotes. It comprises a 
three α-helix bundle structure, whose integrity is required for pre-mRNA 3’end processing and 
the interaction with Pcf11 (Gross and Moore, 2001a; Qu et al., 2007). In the middle lies a 
proline-glycine rich region (40%), inserted with a MEAR(A/G) pentapeptide repeat motif that is 
all α-helical (Richardson et al., 1999; Takagaki et al., 1992). This region does not exist in Rna15 
and its function is currently unspecified.  
CstF-50 is the only CstF subunit that does not have a yeast counterpart. This protein 
contains an N-terminal dimerization domain and seven WD40-repeats at its C-terminus 
(Takagaki and Manley, 1992, 2000) (Figure 2A). The dimerization domain is crucial for its self-
association (Takagaki and Manley, 2000) and together with CstF-77 accounts for the hexameric 
architecture of the whole CstF complex. The crystal structure of this domain suggests a 
formation of 3 tandem α helices tethered to the other protomer, mediated primarily through a 
conserved hydrophobic core (Moreno-Morcillo et al., 2011b) (Figure 2D). A highly conserved 
region was also identified on the surface of the dimer and hence proposed to bind other proteins 
(Moreno-Morcillo et al., 2011b). In addition, the N-terminal domain is necessary for CstF-50 to 
interact with RNAP II CTD (McCracken et al., 1997), although they seem to only associate 
weakly if the rest of CstF-50 is removed (Moreno-Morcillo et al., 2011b). This interaction places 
CstF-50 in an important position in coupling transcription to 3’ end processing.   
Similar to CPSF-160 and WDR33, the WD40 domain of CstF-50 functions as a binding 
platform. Truncation of a single repeat abrogates its interaction with CstF-77 (Takagaki and 
Manley, 2000). This domain may also serve as a regulatory adaptor. In particular, BARD1-
BRCA1, a breast cancer related protein complex that functions in DNA damage repair (Irminger-
	  	  
24 
Finger and Leung, 2002), binds to the WD40 domain of CstF-50 upon DNA damage, and 
thereby strongly but transiently inhibits pre-mRNA 3’ end processing (Kleiman and Manley, 
1999, 2001). It was proposed that this can repress aberrant mRNA 3’ end processing during 
transcription, probably at the damaged DNA positions (Kleiman and Manley, 2001).  
 
Cleavage Factor I (CFI) 
CFI is necessary for cleavage but not polyadenylation (Takagaki et al., 1989). ChIP 
experiments indicate that CFI associates early with the transcription elongation complex, 
alongside with CPSF and CstF, in facilitating transcription-coupled 3’ end processing 
(Venkataraman et al., 2005). At the polyadenylation site, CFI recognizes pre-mRNAs and 
stabilizes the binding of CPSF (Rüegsegger et al., 1996). Unlike other major 3’ end processing 
factors, CFI exists only in metazoans and does not have a yeast equivalent.  
The CFI complex is assembled as a heterotetramer with a dimer of the small subunit 
CFI25 and another two copies of a combination of the large subunits, CFI59, CFI68 or CFI72 
(Kim et al., 2010; Rüegsegger et al., 1996, 1998). CFI59 and CFI68 are encoded by two 
paralogous genes while CFI72 is an isoform of CFI68, possibly generated by alternative splicing 
(Ruepp et al., 2011b). The three large subunits may be functionally redundant because CFI68 
alone is capable of reconstituting CFI activity with CFI25 in vitro (Rüegsegger et al., 1998). 
Meanwhile, all CFI subunits can be UV-crosslinked to pre-mRNAs, suggesting their critical 
roles in RNA recognition (Rüegsegger et al., 1996). SELEX experiments identified a binding 
consensus sequence for CFI: UGUAN (N: A > U > G or C) (Brown and Gilmartin, 2003), which 
was later shown to be an important cis element for poly(A) site definition (Hu et al., 2005; 




Figure 3. Cleavage Factor I (CFI). (A) Domain organization of human CFI subunits. (B) Crystal structure of the 
CFI25-CFI68-RNA complex (PDB ID: 3Q2T (Yang et al., 2011a)).  
 
CFI25 encompasses a central Nudix domain (Dettwiler et al., 2004) (Figure 3A). The 
Nudix superfamily is widespread in all life kingdoms and characterized as mostly 
pyrophosphohydrolases that target nucleoside diphosphate linked to another moiety X 
(McLennan, 2006). These proteins generally perform housekeeping function by removing toxic 
metabolites in the cell (Bessman et al., 1996). Intriguingly, two signature glutamates that are key 
for metal coordination and enzymatic catalysis are missing in the Nudix motif of CFI25 
(GX5EX7REUXEEXGU, U: hydrophobic residue, X: any residue), which therefore distinguishes 
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CFI25 from most other Nudix proteins (McLennan, 2006). The crystal structure of CFI25 shows 
a core Nudix domain featuring a canonical α/β/α fold sandwich augmented with N- and C-
terminal extensions (Coseno et al., 2008; Trésaugues et al., 2008) (Figure 3B). No metal ions 
were observed around the Nudix motif and subsequent biochemical assays failed to detect any 
enzymatic activity, suggesting that CFI25 is unlikely to be a hydrolase (Coseno et al., 2008; 
Trésaugues et al., 2008).  
Despite the lack of hydrolase activity, CFI25 utilizes its Nudix domain as a platform for 
binding other proteins, nucleotides and more importantly, RNA. CFI25 interacts with CFI68, 
PAP and PABPN1 (Dettwiler et al., 2004). It can also bind ATP and Ap4A, albeit with relatively 
low affinity (Coseno et al., 2008). Ap4A was captured in a structure with CFI25, located in a 
binding pocket outside of the Nudix motif (Coseno et al., 2008). The crystal structure of the 
CFI25-RNA complex has been determined, providing insights into the mechanism by which CFI 
specifically recognizes the UGUA element (Yang et al., 2010). Unexpectedly, in addition to the 
Nudix domain, the N-terminal extension also makes direct contact with the RNA (Figure 3B). 
Interactions are achieved mainly through hydrogen bonds formed between RNA bases and the 
main chain or side chains of the protein. Waton-Crick/sugar-edge base interactions within the 
RNA also contribute to the binding specificity (Yang et al., 2010). Moreover, the dimeric nature 
of CFI25 enables it to bind two copies of UGUA elements simultaneously, providing an 
approach through which the poly(A) site can be accurately defined and regulated (see below). 
The large subunit CFI68 is composed of an N-terminal RRM, a middle proline-rich 
region and a C-terminal RS domain with alternating arginine and serine residues (Rüegsegger et 
al., 1998) (Figure 3A). The domain organization resembles SR proteins involved in pre-mRNA 
splicing. In fact, CFI68 was shown to co-purify with the spliceosome (Awasthi and Alwine, 
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2003; Rappsilber et al., 2002; Zhou et al., 2002) and interacts with splicing factors, such as 
U2AF65 and other SR proteins (Dettwiler et al., 2004; Millevoi et al., 2006), suggesting its 
potential role in coordinating pre-mRNA splicing and 3’ end processing. CFI68 also interacts 
with the U7 snRNP and participates in histone mRNA processing (Ruepp et al., 2010). 
The RRM of CFI68 interacts weakly with the RNA but it can be enhanced substantially 
with the cooperative binding of CFI25 (Dettwiler et al., 2004). In the crystal structure of the 
CFI25-CFI68-RNA complex, each CFI68 monomer maintains simultaneous interactions with the 
CFI25 dimer at the opposite side (Li et al., 2011; Yang et al., 2011a) (Figure 3B). The presence 
of CFI68 causes little structural change to the CFI25 dimer, nor does it affect the RNA binding 
specificity (Li et al., 2011; Yang et al., 2011a). Two UGUA RNA sequences are each bound to 
the monomer of CFI25 in an antiparallel fashion. The connecting loop sequence, though not 
included in the structure, is likely to be stabilized by the RRM of CFI68 (Li et al., 2011; Yang et 
al., 2011a). Interestingly, the interaction between the RRM and the RNA substrate does not seem 
to be mediated through the canonical RNA binding site on the central β-sheet, as mutations of 
the conserved putative binding residues had modest effects on the affinity (Li et al., 2011; Yang 
et al., 2011a). Further mutagenesis analysis revealed that the looping of the RNA is facilitated by 
residues in a cleft adjacent to the CFI25-CFI68 interface (Yang et al., 2011a). More importantly, 
based on the structural model, a RNA looping mechanism directed by CFI has been proposed for 
poly(A) selection in APA  (Yang et al., 2011a, 2011b). Simply put, the CFI complex can take 
advantage of different UGUA elements surrounding multiple PAS elements and loop out an 
entire AAUAAA region, resulting in polyadenylation occurring at a distal site (Yang et al., 
2011a, 2011b). This model is consistent with the evidence from several studies indicating that 
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down-regulation of CFI level in cells correlates with widespread usage of proximal poly(A) sites 
(Kim et al., 2010; Kubo et al., 2006; Martin et al., 2012; Sartini et al., 2008).   
 
Cleavage Factor II (CFII) 
Like CFI, CFII is also only required for cleavage but dispensable for polyadenylation 
(Takagaki et al., 1989; de Vries et al., 2000). CFII is arguably the least well-characterized factor 
in the mammalian 3’ end processing complex, partly because its exact components remain poorly 
defined. In an early purification, more than 15 proteins were found in the CFII fraction, although 
most of them may be cross contamination or only play stimulatory roles. Only two proteins, 
Pcf11 and Clp1 co-eluted with the CFII activity (de Vries et al., 2000). Both of these have yeast 
homologs that are essential for yeast pre-mRNA 3’ end formation (Amrani et al., 1997a; 
Minvielle-Sebastia et al., 1997). However, there is no evidence indicating that these two proteins 
alone are capable of reconstituting the CFII activity.  
Most of our understanding on CFII comes from parallel studies in yeast. Both Pcf11 and 
Clp1 are part of the CFIA complex, which also includes Rna14 and Rna15 (CstF homologs). 
Pcf11 plays a pivotal role in the assembly of CFIA as it is the only component in the complex 
that makes direct contacts with all other members. The interacting domains have been mapped to 
the middle and C-terminal regions (Amrani et al., 1997a; Gross and Moore, 2001a; Qu et al., 
2007; Sadowski et al., 2003) (Figure 4A). Two highly conserved zinc fingers were identified 
flanking the C-terminal Clp1-interating domain but their function remains unknown. There is 
also a stretch of 20 consecutive glutamines preceding the middle Rna14-Rna15 binding domain, 





Figure 4. Cleavage Factor II (CFII). (A) Domain organization of the yeast homologs of CFII subunits. (B) Crystal 
structure of the CID of Pcf11 in complex with a CTD peptide (PDB ID: 1SZA (Meinhart and Cramer, 2004)). (C) 
Conformation of the CTD peptide bound to the CID of Pcf11. (D) Crystal structure of the Clp1-Pcf11-ATP complex 
(PDB ID: 2NPI (Noble et al., 2007)) 
 
The N-terminus of Pcf11 features an RNAP II CTD interacting domain (CID), which 
comprises eight α-helices arranged in a right-handed superhelical formation (Meinhart and 
Cramer, 2004; Noble et al., 2005) (Figure 4B). The CID interacts with both unphosphorylated 
and phosphorylated CTD, but it has a higher affinity with the latter (Barillà et al., 2001; 
Licatalosi et al., 2002; Sadowski et al., 2003). Surprisingly, the CID-CTD interaction is not 
necessary for pre-mRNA 3’ end processing, but it is essential for proper transcription termination 
(Barillà et al., 2001; Sadowski et al., 2003). The CID also weakly binds to RNA (Hollingworth et 
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al., 2006) and bridges the CTD to the pre-mRNA in a way that the transcription elongation 
complex can be dismantled (Zhang et al., 2005), supporting a role for Pcf11 in coupling 
transcription to 3’ end processing.  
Human Pcf11 is twice as large as its yeast homolog and only shares sequence homology 
at its N-terminal CID (de Vries et al., 2000). The remainder of human Pcf11 has not been 
characterized. Despite apparent differences in the primary sequence, the function of Pcf11 is 
evolutionarily conserved. Knockdown of Pcf11 in HeLa cells resulted in deficiency in both pre-
mRNA cleavage as well as transcription termination and Pcf11 may also be required for 
degradation of the 3’ end product following cleavage (West and Proudfoot, 2008).  
Clp1 consists of a central ATPase domain and two smaller domains at its N- and C-
terminus (Noble et al., 2007) (Figure 4A). The primary sequence of yeast Clp1 reveals a 
conserved Walker A/P loop motif (de Vries et al., 2000), which is typically involved in 
ATP/GTP binding or catalysis (Walker et al., 1982). Indeed, an ATP molecule was bound to 
Clp1 in the crystal structure (Figure 4D). However, ATPase activity could not be detected for 
Clp1, either on its own or with its binding partners (Noble et al., 2007). Several recent studies 
showed that certain mutations introduced in the ATP-binding pocket could perturb the Clp1-
Pcf11 interaction and in turn cause defects in 3’ end processing and transcription termination 
(Ghazy et al., 2012; Haddad et al., 2012; Holbein et al., 2011), although some of these mutations 
did not affect ATP binding. In the complex structure, the interface between Clp1 and Pcf11 is 
distant from the ATP-binding site. It is possible that ATP acts as a molecular switch that can 
regulate or be affected by the binding partners of Clp1 (Ghazy et al., 2012). Nonetheless, further 
investigation is needed to understand the function of Clp1 ATP binding capability.  
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While yeast Clp1 does not possess catalytic activity, the human homolog is an active 5’-
OH polynucleotide kinase (Weitzer and Martinez, 2007a). The enzymatic activity is required in 
tRNA splicing and can not be complemented by yeast Clp1 (Ramirez et al., 2008; Weitzer and 
Martinez, 2007a, 2007b). Although human Clp1 bears high sequence homology with its yeast 
counterpart, it might have acquired a diverged role during evolution. In pre-mRNA 3’ end 
processing, Clp1 interacts with both CPSF and CFI and likely functions to tether them to CFII 
(de Vries et al., 2000).  
 
Symplekin 
Symplekin was initially identified as a tight junction plaque protein but it is ubiquitously 
expressed in all cell types (Keon et al., 1996). Its association with the pre-mRNA 3’ end 
processing complex was uncovered in a study looking for binding partners of CstF-64 (Takagaki 
and Manley, 2000). Sequence alignment indicated that symplekin bears low primary strucutre 
homology to an essential yeast cleavage and polyadenylation factor Pta1 (Ghazy et al., 2009; 
Preker et al., 1997; Takagaki and Manley, 2000; Zhao et al., 1999b). Pta1 interacts with various 
3’ end processing proteins, including Ysh1 (Zhelkovsky et al., 2006), Ydh1 (Kyburz et al., 2003), 
Fip1 (Ghazy et al., 2009), Pcf11 (Kyburz et al., 2003), Clp1 (Ghazy et al., 2009), Pap1 (Ghazy et 
al., 2009), and Ssu72 (He et al., 2003). Pta1 (and also symplekin) is thus recognized as a scaffold 
protein composed of assorted protein-interacting modules, coordinating the assembly of the 
machinery and tethering relevant components to increase functional efficiency.  
Secondary structure analysis suggests that symplekin consists of all α helices. Based on 
the sequence conservation, partner binding region and homology to Pta1, symplekin can be 
divided into four distinctive domains: an N-
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CstF-64 binding domain, CPSF-73 binding domain and a C-terminal domain that is not present 
in Pta1 and has no known function (Ghazy et al., 2009; Xiang et al., 2010) (Figure 5A).  
Symplekin NTD contains seven pairs of anti-parallel α helices arranged in the shape of an 
arc (Kennedy et al., 2009; Xiang et al., 2010). The overall fold is reminiscent of the ARM or 
HEAT repeats, which is typically involved in protein-protein interactions (Andrade et al., 2001), 
in agreement with its suggested scaffolding function. Similar to Pta1, symplekin NTD interacts 
with Ssu72, an RNAP II CTD phosphatase (Ghazy et al., 2009; Xiang et al., 2010). The crystal 
structure of the symplekin-Ssu72 complex has been determined. Ssu72 binds to symplein NTD at 
the concave surface, mediated by ion-pair, hydrogen-bonding as well as hydrophobic interactions 
(Xiang et al., 2010) (Figure 5B). Interestingly, although the active site of Ssu72 is remote from 
the contact surface, the binding of symplekin NTD can stimulate the phosphatase activity of 
Ssu72, likely through stabilization of the enzyme and/or allosteric regulation (Xiang et al., 2010). 
These results suggest that symplekin may not simply be a passive scaffold, but can also play a 
regulatory role in the 3’ end processing complex. In fact, many scaffold proteins in other systems 
have been reported to assume similar modulating function (Gold et al., 2006; Good et al., 2011; 
Reyes-Turcu et al., 2009).  
The N-terminal domain of Pta1 is not required for in vitro pre-mRNA 3’ end processing 
but the addition of it can inhibit polyadenylation (Ghazy et al., 2009). Symplekin NTD displays a 
similar inhibitory effect when polyadenylation is coupled to transcription (Xiang et al., 2010). 
Ssu72 was able to alleviate the reduction while a catalytically inactive mutant failed, suggesting 
that the enzymatic activity of Ssu72 is indispensible for efficient transcription-coupled 
polyadenylation. A model was proposed in that symplekin brings Ssu72 to remove 
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phosphorylation of Ser5 residues in RNAP II CTD, so that other 3’ end processing factors can be 
recruited to promote polyadenylation (Xiang et al., 2010).  
Symplekin interacts with the hinge region of CstF-64, competitively with CstF-77 
(Takagaki and Manley, 2000; Ruepp et al., 2011a). A CstF-64 mutant whose interaction with 
symplekin was abolished maintained its association with CstF-77 (Ruepp et al., 2011a). This 
mutant did not affect general pre-mRNA cleavage and polyadenylation but impaired histone pre-
mRNA 3’ end processing (Ruepp et al., 2011a). It appears that CstF-64 associates exclusively 
with either CstF-77 or symplekin in two separate pre-mRNA processing complex and perform 
distinct functions. Interestingly, the equivalent region of Pta1 does not interact with Rna15 but 
instead binds to Pti1 (Ghazy et al., 2009; Zhelkovsky et al., 2006), an Rna15 paralog involved in 
small nucleolar RNA 3’ end processing (Dheur et al., 2003). 
Symplekin also interacts with CPSF-73. The binding region was deduced based on 
sequence conservation with Pta1 and the fact that the C-terminal domain of Pta1 interacts with 
the C-terminal domain of Ysh1 (Zhelkovsky et al., 2006; Ghazy et al., 2009). Symplekin tightly 
associates with CPSF-73 as well as CPSF-100 (Hofmann et al., 2002; Sullivan et al., 2009). They 
comprise a shared stable core complex for both general and histone pre-mRNA 3’ end processing 
(Sullivan et al., 2009). As a consequence, it has been speculated that symplekin may regulate the 
nuclease activity of CPSF-73 through direct interactions (Dominski, 2010; Sullivan et al., 2009), 
but further investigation is necessary to test this hypothesis.  
Besides general mRNA 3’ end processing, symplekin participates in a variety of 
important cellular processes. Symplekin provides the scaffold in histone mRNA 3’ end 
processing (Kolev and Steitz, 2005). It is also required for CPEB (Cytoplasmic polyadenylation 
element binding protein)-mediated cytoplasmic polyadenylation (Barnard et al., 2004). 
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Furthermore, symplekin has been implicated in maintaining mitotic fidelity by supporting 
microtubule dynamics (Cappell et al., 2010) as well as promoting tumorigenesis in human 
intestinal epithelial cells (Buchert et al., 2010).  
 
RNA polymerase II largest subunit C-terminal domain (RNAP II CTD) 
The largest subunit of RNAP II contains an extended C-terminal domain that separates it 
from the globular core structure (Cramer et al., 2001). The CTD consists a stretch of consensus 
repeats Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (Allison et al., 1985; Corden et al., 1985). The 
number of the repeats varies across eukaryotic organisms, in particular 52 in vertebrates and 26 
in yeast (Chapman et al., 2008; Liu et al., 2010). The flexible and repetitive nature of the CTD 
enables it to provide a perfect platform for the binding of a variety of protein factors, through 
which RNAP II transcription can be coordinated with other nuclear events (reviewed in 
Bartkowiak et al., 2011; Hsin and Manley, 2012; Zhang et al., 2012; Heidemann et al., 2013) 
The CTD was first linked to 3’ end processing in a study showing that the truncation of 
the CTD from RNAP II resulted in defects in cleavage and polyadenylation in vivo (McCracken 
et al., 1997).  The CTD was shown to be essential for efficient 3’ end processing in vitro (Hirose 
and Manley, 1998). Exactly how the CTD promotes mRNA 3’ end formation is still not well 
understood. A platform role has been proposed since a number of 3’ end processing factors have 
been observed binding to the CTD, such as Ydh1 (Kyburz et al., 2003), Yhh1 (Dichtl et al., 
2002), CstF-77/Rna14 (McCracken et al., 1997; Sadowski et al., 2003), CstF-50 (McCracken et 
al., 1997), Pcf11 (Barillà et al., 2001; Licatalosi et al., 2002; Meinhart and Cramer, 2004; 
Sadowski et al., 2003) and perhaps Rna15 (Sadowski et al., 2003) and Pta1 (Rodriguez et al., 
2000). The association between the CTD and some 3’ end processing factors can be traced back 
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to the promoter region and is likely maintained through elongation to the 3’ end (Dantonel et al., 
1997; Nag et al., 2007; Kim et al., 2010; Mayer et al., 2010, 2012). 
The ability of the CTD to orchestrate transcription to 3’ end processing and other mRNA 
processing events is primarily a result of its structural diversity, which can be summarized in 
three ways. First, the largely unfolded repeats create significant variations in the 3D structure. 
The free CTD was initially proposed to form β-turns (Suzuki, 1989) and this conformation has 
also been observed in both NMR experiments (Cagas and Corden, 1995; Harding, 1992) and 
crystal structures (Meinhart and Cramer, 2004). Later studies however indicate that the CTD 
adopts a non-uniform and overall disordered architecture in solution (Bienkiewicz et al., 2000; 
Noble et al., 2005), allowing various interactions formed with other proteins through an induced 
fit mechanism (see review Meinhart et al., 2005). Second, post-translational modifications on 
signature residues can affect CTD recognition of other factors by altering its chemical structure 
(see reviews Jasnovidova and Stefl, 2013; Meinhart et al., 2005). It is now clear that all five 
residues with a hydroxyl group (Tyr1, Ser2, Thr4, Ser5 and Ser7) can be phosphorylated, 
generating a combinatorial CTD code. This code not only changes dynamically throughout the 
transcription cycle but it also patterns in a gene-specific manner (see reviews: Egloff et al., 2012; 
Heidemann et al., 2013; Hsin and Manley, 2012; Zhang et al., 2012). In addition to 
phosphorylation, other modifications have also been identified on the CTD, such as 
glycosylation (Ranuncolo et al., 2012), methylation (Sims et al., 2011) and ubiquitination (Li et 
al., 2007), further complicating the CTD code. Third, the peptide bonds of Ser2-Pro3 and Ser5-
Pro6 are subject to cis-trans isomerization, which can produce drastic conformational changes to 
the CTD structure, allowing selective binding of processing factors (see review Jasnovidova and 
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Stefl, 2013). All three layers together make the CTD so structurally versatile and elaborate that it 
is able to coordinate related processes to transcription in a coupled manner.  
Although structural information of the complete CTD is not available, a number of pieces 
ranging from less than one repeat to nearly three repeats have been captured associated with 
CTD binding proteins. These CTD structures present immensely diverse conformations and 
modifications (see reivews Jasnovidova and Stefl, 2013; Meinhart et al., 2005). Here we will 
only briefly discuss two that are closely related to pre-mRNA 3’ end processing.  
The first is the Pcf11-pSer2 CTD complex (Figure 4B). In this structure, the bound CTD 
adopts a β-turn conformation (Meinhart and Cramer, 2004), which however is likely formed via 
induced fit through the binding of Pcf11, because NMR experiments suggest that a similar CTD 
peptide exists as a dynamic unfolded ensemble in solution (Noble et al., 2005). It had been 
suggested that phosphorylation at Ser2 can enhance binding of Pcf11 (Barillà et al., 2001; 
Sadowski et al., 2003), but the phosphate group of Ser2 does not make direct contacts with Pcf11 
and therefore unlikely contributes to the interaction (Figure 4C). Instead, it forms hydrogen 
bonds within the CTD, in a way that indirectly stabilizes the β-turn structure (Meinhart and 
Cramer, 2004). By iterating the observed CTD repeat, Meinhart et al. deduced a complete CTD 
model as a compact β-spiral. While Ser2 phosphorylation can be readily accommodated in the 
model, Ser5 phosphorylation would open up the spiral and induce a more extended structure. 
With dynamic phosphorylation and de-phosphorylation, the CTD conformations would be 
altered and cycled, so that the spatial and temporal control of mRNA processing factor binding 




Figure 5. Other mammalian pre-mRNA 3’ end processing factors. (A) Domain organization of human symplekin, 
PAP and PABPN1. (B) Crystal structure of the symplekin-Ssu72-CTD peptide complex (PDB ID: 3O2Q (Xiang et 
al., 2010)). (C) Conformation of the CTD peptide in the active site of Ssu72. (D) Crystal structure of the RRM dimer 
of PABPN1 (PDB ID: 3B4M (Ge et al., 2008)). (E) Crystal structure of the yeast Pap1 in complex with ATP and 
oligo(A) sequence (PDB ID: 2Q66 (Balbo and Bohm, 2007)).  
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The second one is the Ssu72-pSer5 CTD complex (Figure 5B). Surprisingly, the CTD 
captured in the active site of Ssu72 has the peptide bond between pSer5 and Pro6 in the cis 
configuration (Figure 5C). This contrasts to all earlier known CTD structures, which were 
exclusively in trans (Xiang et al., 2010; Werner-Allen et al., 2011). The substrate-binding pocket 
of Ssu72 has a confined space so that only the CTD with pSer5-Pro6 in cis configuration can be 
accommodated. The selectivity of Ssu72 nonetheless severely limits its substrate availability, 
because less than 20% of the total population of the pSer5-Pro6 peptide bond exists in the cis 
configuration and the natural cis-trans conversion is rather slow (Werner-Allen et al., 2011; 
Xiang et al., 2010). Therefore, peptidyl-prolyl isomerases (Pin1 in human and Ess1 in yeast) can 
promote de-phosphorylation of the CTD by accelerating the cis-trans conversion, which presents 
a higher level regulation of the CTD function (Krishnamurthy et al., 2009; Singh et al., 2009; 
Xiang et al., 2010; Werner-Allen et al., 2011).  
 
Poly(A) polymerase (PAP) 
PAP catalyzes the second step of pre-mRNA 3’ end processing: polyadenylation. In the 
presence of Mn2+ in vitro, PAP is capable of nonspecifically polyadenylating RNA primers on its 
own but it exhibits distributive feature (Raabe et al., 1991; Wahle, 1991b). Under physiological 
condition where Mg2+ is used, polyadenylation by PAP occurs in a PAS-dependent manner. 
CPSF is required to confer processivity and specificity (Takagaki et al., 1988). This specific 
polyadenylation can be further boosted by PABPN1 (discussed below). In mammals, PAP is also 
in most cases indispensible for the cleavage reaction (Christofori and Keller, 1988; Takagaki et 
al., 1988).   
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PAP belongs to the DNA polymerase β family (Edmonds, 1990). The first 500 residues 
of PAP are conserved throughout eukaryotic species (Martin and Keller, 1996; Martin et al., 
2000). Crystal structures of bovine PAP and yeast PAP (Pap1) have been determined, revealing a 
three-globular-domain organization (Bard et al., 2000; Martin et al., 2000) (Figure 5E). A large 
open central cleft harboring the active site is encompassed by the three domains. Upon substrate 
binding, the cleft closes as the N- and C-terminal domains interact (Balbo and Bohm, 2007), 
suggesting an induced-fit mechanism for the enzyme, which is consistent with earlier 
experiments (Balbo et al., 2005, 2007; Martin et al., 2004). Vertebrate PAP has a C-terminal 
extension of ~20 kD that does not exist in lower eukaryotes and is not essential for 
polyadenylation activity (Martin and Keller, 1996) (Figure 5A). This extension is enriched with 
serines and threonines, which are targets for modulating PAP activity and are subject to various 
post-translational modifications, including phosphorylation (Colgan et al., 1996), acetylation 
(Shimazu et al., 2007), sumoylation (Vethantham et al., 2008) and PARylation (Di Giammartino 
et al., 2013). 
PAP has been shown to interact with many protein factors in the pre-mRNA 3’ end 
processing complex, such as CPSF-160 (Murthy and Manley, 1995) and CFI25 (Dettwiler et al., 
2004). In yeast, Pap1 binds to both the N-terminal domain of Pta1 and Yhh1 through its own N-
terminal domain (Ezeokonkwo et al., 2012). The C-terminal domain of Pap1 interacts with Fip1 
(Helmling et al., 2001; Meinke et al., 2008; Preker et al., 1995), with a complex structure 




Figure 6. Mammalian pre-mRNA 3’ end processing machinery. (A) A wire map of the interaction network of 
mammalian pre-mRNA 3’ end processing machinery, also a diagram summary of Table 1. Thick double lines 
represent interactions observed in both mammalian and yeast systems. Solid lines represent interactions studied only 
in mammals while dashed lines represent interactions studied only in yeast. (B) A visionary model of mammalian 
pre-mRNA 3’ end processing machinery. Cis-elements are highlighted in boxes on the pre-mRNA. Red arrow 
indicates the cleavage site.  
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Poly(A) binding protein (PABPN1) 
The first poly(A) binding protein was identified in the cytoplasm (Blobel, 1973). 
Cytoplasmic poly(A) binding proteins (PABPC) exist in all eukaryotes (Adam et al., 1986) and 
play essential roles in translation control and mRNA decay (Kühn and Wahle, 2004; Mangus et 
al., 2003). The identity of the nuclear poly(A) binding protein (PABPN1) involved in pre-mRNA 
3’ end processing was not unearthed until almost two decades later (Nemeth et al., 1995; Wahle, 
1991a). PABPN1 serves as another specificity factor in addition to CPSF for PAP in PAS-
dependent polyadenylation (Wahle, 1991a). The presence of either CPSF or PABPN1 only 
provides moderate processivity, but together they promote rapid poly(A) elongation to 
approximately 200-300nt in length (Bienroth et al., 1993; Wahle, 1995), which matches average 
newly synthesized poly(A) tails in vivo (Brawerman, 1981). PABPN1 not only ensures the 
proper length of the poly (A) tail, but it may also be a key regulator in APA (Jenal et al., 2012).  
Mammalian PABPN1 has a molecular weight of ~33 kD and a domain architecture very 
different from PABPC (Figure 5A). The N-terminal domain is acidic and rich in glutamates and 
may function to prevent undesirable contacts between PAP and PABPN1, as removal of this 
domain can enhance their interactions (Kerwitz et al., 2003). The middle region contains a coiled 
coil (CC) domain that is required for stimulation of PAP (Kerwitz et al., 2003). Immediately 
following the CC is a canonical RRM, whose structure indicates that it forms a dimer (Ge et al., 
2008) (Figure 5D). This is compatible with the earlier observation that the C-terminal domain 
(arginine-rich) of PABPN1 can also self-associate. In fact, in the absence of poly(A) and at 
elevated concentrations, PABPN1 is prone to aggregation into oligomers (Keller et al., 2000; 
Nemeth et al., 1995).  
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Each PABPN1 can recognize a ~10nt poly(A) sequence specifically (Nemeth et al., 
1995). Both the RRM motif and the C-terminal domain are required for RNA binding (Kühn et 
al., 2003). As polyadenylation proceeds, PABPN1 coats the poly(A) tail sequentially, forming a 
linear filament or a spherical particle up to 21nm in diameter (Keller et al., 2000). This structure 
is thought to restrict CPSF to the PAS while facilitating the physical interaction between CPSF 
and PAP over the newly synthesized poly(A) sequence until a desired length is reached (Kühn et 
al., 2009).  
In yeast, PABPN1 has a sequence homolog Rbp29, but this protein localizes in the 
cytoplasm and has a very different function (Winstall et al., 2000). The true functional 
counterpart of PABPN1 is still under debate. Two candidates are Pab1 and Nab2. Pab1 
associates with CFIA and can regulate poly(A) tail length either on its own or through the 
poly(A) nuclease PAN-dependent pathway (Amrani et al., 1997b; Brown and Sachs, 1998; 
Minvielle-Sebastia et al., 1997). However, Pab1 resembles PABPC and is predominantly 
cytoplasmic, arguing it is equivalent to PABPN1. The nuclear protein Nab2 is involved in 
mRNA export and has also been shown to control poly(A) synthesis in vitro and in vivo (Dheur 
et al., 2005; Hector et al., 2002; Viphakone et al., 2008). In contrast to PABPN1, Nab2 does not 
have an RRM and instead binds to the RNA though its zinc finger (Anderson et al., 1993). 
Nevertheless, both Pab1 and Nab2 negatively modulate poly(A) length, which is opposite to the 
stimulatory effect of PABPN1. 
 
Perspective 
Since the start of the second millennium when the first protein structure of a component 
of the pre-mRNA 3’ end processing complex was reported (PAP; Bard et al., 2000; Martin et al., 
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2000), structural studies in this field have flourished and advanced our knowledge of this 
intricate process at an ever-increasing pace. They have been proven to be an invaluable source of 
knowledge, when combined with hypothesis-driven biochemical and functional 
characterizations, to help us understand the mechanistic details of the machinery. A handful of 
structures of protein factors have been determined and analyzed (Table 2), but compared to the 
complicated machinery, what we know is only the tip of the iceberg. Many key proteins have not 
yet been structurally characterized. For example, how CPSF-160 recognizes the PAS and at the 
same time orchestrates interactions with other protein factors is still elusive. It will be of great 
interest to obtain its structure and dissect its binding specificity. More importantly, past studies 
have focused on individual proteins or even domains rather than looking at the bigger picture. To 
understand in detail how the polyadenylation complex is assembled and functions as a whole, we 
will need a more complete structural blueprint (Figure 6). In recent years, several complex 
structures have been determined, such as CFI complex (Li et al., 2011; Yang et al., 2011a), 
symplekin-Ssu72-CTD complex (Xiang et al., 2010) and Rna14-Rna15 complex (Moreno-
Morcillo et al., 2011a; Paulson and Tong, 2012), which substantially facilitated the molecular 
mapping of protein interconnections.  Nevertheless, structural information on protein complexes 
in the 3’ end processing machinery is still limited and confined within sub-complexes. How 
different sub-complexes associate and coordinate in the recruitment process and also the 
enzymatic reactions is largely unclear. On the other hand, an EM study examining the whole 3’ 
end processing complex has provided us an unparalleled first look at the overall architecture and 
may provide a powerful future approach (Shi et al., 2009).  Finally, the coupling of 3’ end 
processing to other nuclear events inevitably raises the complexity, but also opens up an 
interesting and emerging direction in which analyses can be performed on bridging factors from 
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a structural perspective, so as to visualize how coupling is achieved and also how cleavage and 





Table 1. Protein interactions studied in both mammalian and yeast pre-mRNA 3’ end processing 
machinery 
Protein partner source method reference 
CPSF-73 (C-
terminus) 




(Dominski et al., 
2005a)  
Ysh1 Ydh1 S. cerevisiae GST pull-
down 
(Kyburz et al., 2003)  




(Tacahashi et al., 
2003)  
Ysh1 Pfs2 S. cerevisiae GST pull-
down 
(Ohnacker et al., 
2000)  
Ysh1 Pcf11 S. cerevisiae GST pull-
down 
(Ghazy et al., 2012; 
Kyburz et al., 2003)  
Ysh1  Clp1 S. cerevisiae GST pull-
down 
(Kyburz et al., 2003)  
Ysh1 (C-
terminus) 
Pta1 (C-terminus) S. cerevisiae Yeast two 
hybrid, GST 
pull-down 
(Ghazy et al., 2009; 
Zhelkovsky et al., 
2006)  
Ydh1 Yhh1 S. cerevisiae GST pull-
down 
(Kyburz et al., 2003)  
Ydh1 Pcf11 S. cerevisiae GST pull-
down 
(Kyburz et al., 2003)  
Ydh1 Pta1 S. cerevisiae GST pull-
down 
(Ghazy et al., 2009; 
Kyburz et al., 2003)  




S. cerevisiae Yeast two 
hybrid & GST 
pull-down 
(Kyburz et al., 2003)  
CPSF-30 RNAP II body H. sapiens Immuno-pull-
down 











(Barabino et al., 
1997, 2000; 
Helmling et al., 
2001)  
Yth1 ZF4 Fip1 S. cerevisiae GST pull-
down 










(Bai et al., 2007; 
Murthy and Manley, 
1995)  
CPSF-160 PAP H. sapiens Immuno-pull-
down 
(Murthy and Manley, 
1995)  
CPSF-160 TAFII20, TAFII55, 
TAFII100 
H. sapiens His-pull-down (Dantonel et al., 
1997)  
Yhh1 Pcf11 S. cerevisiae GST pull-
down 
(Kyburz et al., 2003)  
Yhh1 Clp1 S. cerevisiae GST pull-
down  
(Kyburz et al., 2003)  
Yhh1 Rna14 S. cerevisiae GST pull-
down 
(Ghazy et al., 2012; 
Kyburz et al., 2003)  
Yhh1 RNAP II CTD 
phosphorylated 
S. cerevisiae Yeast two 
hybrid & GST 
pull-down 
(Dichtl et al., 2002)  
Yhh1 Pap1 N-terminal 
domain 
S. cerevisiae GST pull-
down 







PAP H. sapiens GST pull-
down 






CPSF-30 H. sapiens GST pull-
down 
(Kaufmann et al., 
2004)  
Fip1  CPSF-160 H. sapiens GST pull-
down 









CstF-77 H. sapiens GST pull-
down 






S. cerevisiae Yeast two 
hybrid, 
immune-pull-




(Helmling et al., 
2001; Meinke et al., 
2008; Preker et al., 
1995)  
Fip1 Rna14 S.cerevisiae Immuno-pull-
down 
(Preker et al., 1995)  
Fip1 Pta1 S. cerevisiae GST pull-
down 
(Ghazy et al., 2009)  
Pfs2 Rna14 S. cerevisiae GST pull-
down 
(Ohnacker et al., 
2000)  
Pfs2 Fip1 S. cerevisiae GST pull-
down 
(Ohnacker et al., 
2000)AM 
Pfs2 Clp1 S. cerevisiae GST pull-
down 







H. sapiens Far-western, 
His pull-down 
(Bai et al., 2007; 
Hockert et al., 2010; 
Takagaki and 
Manley, 2000)  
CstF-77 RNAP II CTD H. sapiens GST pull-
down (weak) 
(McCracken et al., 
1997)  




















(Gross and Moore, 
2001a; Legrand et 
al., 2007; Moreno-
Morcillo et al., 
2011a; Paulson and 
Tong, 2012)  
Rna14 Pcf11 S. cerevisiae Yeast two 
hybrid, GST 
pull-down 
(Amrani et al., 
1997a; Gross and 




Hrp1 (RRM) S. cerevisiae GST pull-
down, NMR 
(Barnwal et al., 
2012; Gross and 






H. sapiens Far-western (Ruepp et al., 2011a; 
Takagaki and 
Manley, 2000)  
Rna15 Pcf11 S. cerevisiae Yeast two 
hybrid, GST & 
MBP pull-
down 
(Amrani et al., 
1997a; Gross and 
Moore, 2001a; Qu et 
al., 2007)  




(Leeper et al., 2010)  
Rna15 RNAP II CTD S. cerevisiae Yeast two 
hybrid 
(Sadowski et al., 
2003)  
CstF-50 RNAP II CTD H. sapiens GST pull-
down 








H. sapiens Far-western (Takagaki and 









Manley, 1999)  
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CFI25 CFI68 (RRM 
domain) 
H. sapiens GST pull-




(Dettwiler et al., 
2004; Li et al., 2011; 
Rüegsegger et al., 
1998; Yang et al., 
2011a) 
CFI25 PAP H. sapiens GST pull-
down 
(Dettwiler et al., 
2004)  
CFI25 PABPN1 H. sapiens GST pull-
down 







H. sapiens Yeast two 
hybrid, co-IP 
(Dettwiler et al., 
2004)  





AM(Barillà et al., 
2001; Licatalosi et 
al., 2002; Meinhart 
and Cramer, 2004; 
Sadowski et al., 
2003) 
Pcf11 Pta1 S. cerevisiae GST pull-
down 
(Ghazy et al., 2009; 
Kyburz et al., 2003)  
hClp1 CFI H. sapiens GST pull-
down 
(de Vries et al., 
2000)  
hClp1 CPSF-100 H. sapiens GST pull-
down 
(de Vries et al., 
2000)  
Clp1 Pcf11 S. cerevisiae GST pull-




(Gordon et al., 2011; 
Gross and Moore, 
2001a; Noble et al., 
2007)  
Clp1 Pta1 S. cerevisiae GST pull-
down 
(Ghazy et al., 2009, 
2012)  
Clp1 Ssu72 S. cerevisiae GST pull-
down 

















(Xiang et al., 2010; 





Ssu72 S. cerevisiae Yeast two 
hybrid, GST 
pull-down 
(Ghazy et al., 2009; 
He et al., 2003)  
Pta1 Pap1 S. cerevisiae Yeast two 
hybrid, GST 
pull-down 
(Ezeokonkwo et al., 
2012; Ghazy et al., 
2009)  
Pta1 RNAP II CTD 
phosphorylated 









B. taurus GST pull-
down 
(Kerwitz et al., 2003)  
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Table 2. Reported structures of protein factors in mammalian or yeast pre-mRNA 3’ end 
processing complex 
 
Protein Note Source PDB Reference 
CPSF-73 Residue 1-460 H. sapiens 2I7T, 
2I7V 
(Mandel et al., 2006a) 
Ydh1 Residue 1-720 S. cerevisiae 2I7X (Mandel et al., 2006a) 
CPSF-30 Zinc finger 2 & 
3, in complex 
with influenza 
A NS1A 
H. sapiens 2RHK (Das et al., 2008) 
CstF-77 HAT domain M. musculus 2OND, 
2OOE 
(Bai et al., 2007) 
CstF-77 HAT domain E. cuniculi 2UY1 (Legrand et al., 2007) 
CstF-64 RRM domain, 
residue 1-111 





H. sapiens 2J8P (Qu et al., 2007) 
CstF-50 Residue 1-65 D. melanogaster 2XZ2 (Moreno-Morcillo et al., 
2011b) 
Rna14 HAT domain K. lactis 4E6H, 
4E85 
(Paulson and Tong, 
2012) 
Rna14 & Rna15 
complex 
C-terminal 
domain & hinge 
domain 
S. cerevisiae 2L9B (Moreno-Morcillo et al., 
2011a) 
Rna14 & Rna15 
complex 
Full length & 
hinge domain 
K. lactis 4EBA (Paulson and Tong, 
2012) 
Rna15 RRM domain, 
residue 16-111 
S. cerevisiae 2X1B (Pancevac et al., 2010) 
Rna15 & RNA 
complex 
RRM domain S. cerevisiae 2X1A, 
2X1F 
(Pancevac et al., 2010) 
Rna15 & Hrp1 
in complex with 
a RNA 
RRM domain in 
Rna15, 2 RRM 
domains in 
Hrp1 
S. cerevisiae 2KM8 (Leeper et al., 2010) 
CFI25 Residue 21-227, 
apo form or 
with a sulfate 
H. sapiens 2CL3, 
2J8Q 
(Trésaugues et al., 2008) 
CFI25 Full length, apo 
form or with 
Ap4A 
H. sapiens 3BAP, 
3BHO 





with two RNA 
sequences 
H. sapiens 3MDI, 
3MDG 
(Yang et al., 2010) 
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CFI25 & CFI68 
in complex with 
RNA 
RRM domain of 
CFI68, 










563 of Pcf11, 
ATP bound 
S. cerevisiae 2NPI (Noble et al., 2007) 
Pcf11 CID domain S. cerevisiae 1SZ9, 
2BFO 
(Meinhart and Cramer, 
2004; Noble et al., 2005) 
Pcf11 in 
complex with 
RNAP II CTD 














H. sapiens 3O2T, 
3ODR, 
3ODS 











H. sapiens 3O2S, 
3O2Q 










at Ser5, or both 
Thr4 and Ser5 
D. melanogaster 4IMJ, 
4IMI 
(Luo et al., 2013) 
Pap1 Complex with 
3’-dATP 
S. cerevisiae 1FA0, 
201P, 
2HHP 
(Balbo et al., 2007; Bard 











S. cerevisiae 3C66 (Meinke et al., 2008) 
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PAP Residue 1-513, 
in complex with 
3’-dATP and 
Mn2+ or Mg2+ 
B. taurus 1F5A, 
1Q78, 
1Q79 
(Martin et al., 2000, 
2004) 
PABPN1 RRM domain H. sapiens 3B4D, 
3B4M 
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Crystal structure of the human symplekin–Ssu72–
CTD phosphopeptide complex
Kehui Xiang1, Takashi Nagaike1*, Song Xiang1*{, Turgay Kilic1, Maia M. Beh1, James L. Manley1 & Liang Tong1
Symplekin (Pta1 in yeast) is a scaffold in the large protein complex
that is required for 39-end cleavage and polyadenylation of eukary-
oticmessengerRNAprecursors (pre-mRNAs)1–4; it also participates
in transcription initiation and termination by RNA polymerase II
(Pol II)5,6. Symplekinmediates interactions betweenmany different
proteins in thismachinery1,2,7–9, although themolecular basis for its
function is not known. Here we report the crystal structure at 2.4Å
resolution of the amino-terminal domain (residues 30–340) of
human symplekin in a ternary complex with the Pol II carboxy-
terminal domain (CTD) Ser 5 phosphatase Ssu72 (refs 7, 10–17)
and a CTD Ser 5 phosphopeptide. The N-terminal domain of
symplekin has the ARM or HEAT fold, with seven pairs of anti-
parallel a-helices arranged in the shape of an arc. The structure of
Ssu72 has some similarity to that of low-molecular-mass phospho-
tyrosine protein phosphatase18,19, although Ssu72 has a unique
active-site landscape as well as extra structural features at the C
terminus that are important for interaction with symplekin.
Ssu72 is bound to the concave face of symplekin, and engineered
mutations in this interface can abolish interactions between the two
proteins. The CTDpeptide is bound in the active site of Ssu72, with
the pSer 5-Pro 6 peptide bond in the cis configuration, which con-
trasts with all other known CTD peptide conformations20,21.
Although the active site of Ssu72 is about 25Å from the interface
with symplekin, we found that the symplekin N-terminal domain
stimulates Ssu72 CTD phosphatase activity in vitro. Furthermore,
the N-terminal domain of symplekin inhibits polyadenylation in
vitro, but only when coupled to transcription. Because catalytically
active Ssu72 overcomes this inhibition, our results show a role for
mammalian Ssu72 in transcription-coupled pre-mRNA 39-end
processing.
Human symplekin contains 1,274 amino-acid residues (Fig. 1a) and
its sequence is well conserved in higher eukaryotes (Supplementary
Fig. 1). In comparison, symplekin shares onlyweak sequence similarity
with yeast Pta1 (ref. 1) (Supplementary Fig. 2), and Pta1 lacks the C-
terminal 500 residues of symplekin (Fig. 1a). Symplekin and Pta1 do
not have any recognizable homology with other proteins. Predictions
of secondary structure suggest the presence of an all-helical segment in
the N-terminal region of symplekin and Pta1 (Fig. 1a and Supplemen-
tary Figs 1 and 2). Recent studies in yeast suggested that theN-terminal
segment of Pta1 is important for interactionwith Ssu72 (ref. 9). Ssu72 is
required for pre-mRNA 39-end cleavage in yeast7, although its phos-
phatase activity is not necessary for this function13. The catalytic activity
of Ssu72may instead be important for Pol II transcription and termina-
tion and for gene looping17. Ssu72 is highly conserved in the eukaryotes
(Supplementary Fig. 3), but so far no evidence exists implicating mam-
malian Ssu72 in 39-end processing.
To determine the structure of a symplekin–Ssu72–CTD phospho-
peptide ternary complex, residues 30–360 of human symplekin and
full-length human Ssu72 were overexpressed and purified separately.
The two proteins were mixed, with Ssu72 in slight molar excess, and
the symplekin–Ssu72 complexwas purified by gel-filtration chromato-
graphy. This procedure also demonstrated strong interactions between
the two human proteins, consistent with observations on their yeast
counterparts9. The decamer CTD phosphopeptide used in this study,
Ser-Tyr 1-Ser 2-Pro 3-Thr 4-pSer 5-Pro 6-Ser 7-Tyr-Ser, where Ser 5 is
phosphorylated, contained an entire CTD heptad repeat as well as a
serine residue from the previous repeat andTyr-Ser from the following
repeat. To prevent hydrolysis, the active-site nucleophile Cys 12 of
Ssu72 was mutated to Ser in the ternary complex. We have also deter-
mined the crystal structure of the symplekin–Ssu72(wild-type) binary
complex and the structures of the symplekinN-terminal domain alone
(for residues 30–395 or 1–395). All the structures are in excellent
agreement with the crystallographic data and the expected geometric
parameters (Supplementary Table 1).
*These authors contributed equally to this work.
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Figure 1 | Structure of the human symplekin–
Ssu72–CTD phosphopeptide ternary complex.
a, Domain organization of human symplekin and
Saccharomyces cerevisiae Pta1. The domains are
suggested by secondary-structure predictions, and
themiddle region of Pta1 is suggested by functional
studies9. b, Schematic drawing of the structure of
human symplekin–Ssu72–CTD phosphopeptide
ternary complex, in two views. The N-terminal
domain of symplekin is shown in cyan, and Ssu72
in yellow. The CTD phosphopeptide is shown as a
stick model (in green for carbon atoms). c, Overlay
of the structures of the N-terminal domain of
human (in cyan) and Drosophila (in grey)
symplekin22. Drosophila symplekin lacks the last
two pairs of helical repeats (boxed). All structure
figures were produced with PyMOL (http://
www.pymol.org).
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The structures show that residues 30–340 of symplekin (Symp-N)
form seven pairs of antiparallel a-helices, whereas residues 1–29 and
341–395 are disordered (Supplementary Fig. 1). The pairs of helices are
arranged in an arc, with the first helix in each pair, the aA helix, being
located on the convex face of the arc, and the aB helix on the concave
face (Fig. 1b).Most of the loops connecting the helices are short, except
for that linking helices a4B and a5A, with 31 residues (Fig. 1b). The
overall fold of Symp-N is found in many other proteins, including
those with the ARM or HEAT repeats. These structures are often
involved in protein–protein interactions, which is consistent with
the proposed scaffold function of symplekin.
The structure of the N-terminal domain of Drosophila symplekin
(residues 22–270) was reported recently22. Its overall conformation is
similar to that of human Symp-N, with a root mean squared distance
of 1.0Å among their equivalent Ca atoms, although theDrosophila sym-
plekinstructure lacks the twopairsofhelices(a6anda7)at theCterminus
(Fig. 1c).Noting thegoodsequence conservationof residues in this region
(Supplementary Fig. 1), it is likely that these helices are also present in
theN-terminal domain ofDrosophila symplekin. Our studies show that
helix a6B is important for interactions with Ssu72 (Fig. 1b; see below).
ThestructureofSsu72containsacentral five-strandedb-sheet (b1–b5)
that is surrounded by helices on both sides (Fig. 2a and Supplementary
Fig. 4). The closest structural homologue of Ssu72 is the low-molecular-
mass phosphotyrosine protein phosphatase (Fig. 2b)18,19, as suggested
previously11,12,14, even though the twoproteins share only 16% sequence
identity. However, our studies show that Ssu72 possesses three unique
structural features compared with this other phosphatase (Fig. 2b),
which are formed by highly conserved residues (Supplementary Fig.
3) and have important functions. A small, two-stranded antiparallel
b-sheet (b2A and b2B) is located near the active site (Fig. 2a). The
aD helix is in a different conformation in Ssu72 and also contributes
to phosphopeptide binding. Finally, Ssu72 contains an extra helix (aG)
and a b-strand (b5) at the C terminus, which are essential for interac-
tions with symplekin (Fig. 1b).
Our structure of the ternary complex showed that the CTDphospho-
peptide, with good electrondensity for residuesThr 4 to Ser 7 (Fig. 2c), is
bound with the peptide bond between pSer 5 and Pro6 in the cis con-
figuration (Fig. 2d). This is in sharp contrast to the conformations of the
CTD phosphopeptides observed in other structures, which all have the
Pro residue(s) in the trans configuration (Supplementary Fig. 5)20,21.
With the cis configuration, the backbone of the phosphopeptide makes
a 180u turn at the pSer-Pro residues, whereas the peptide in the trans
configuration (Supplementary Fig. 5) would clash with Ssu72.




































































Figure 2 | Recognition of the CTD phosphopeptide by human Ssu72.
a, Schematic drawing of the structure of human Ssu72–CTD phosphopeptide
complex. b, Overlay of the structures of Ssu72 (yellow) and low-molecular-
mass phosphotyrosine protein phosphatase (grey)18,19. Arrows indicate unique
structural features in Ssu72. Stereo versions of a and b are given in
Supplementary Fig. 4. c, Two views of the omit Fo2 Fc electron density at 2.4Å
resolution for the CTD phosphopeptide, contoured at 3s. d, Stereo pair
showing detailed interactions between the CTDphosphopeptide and the active
site of Ssu72. Ion-pair and hydrogen-bonding interactions are indicated by red
dashed lines. e, Molecular surface of the active-site region of Ssu72. The CTD
phosphopeptide is shown as a stick model.
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with the pSer-Pro peptide bond in the cis configuration, in contrast to all
other known CTD phosphatases (Supplementary Information).
Our observation of a cis configuration for the CTD also provides a
different interpretation for the role of the peptidyl-prolyl isomerase
Pin1 (Ess1 in yeast) in regulating Pol II transcription23–25. It has been
proposed that Pin1/Ess1 promotes the trans configuration of the CTD
for dephosphorylation by Ssu72 (refs 24, 25), whereas our structure
indicates that the opposite must be true. Our in vitro phosphatase
assays demonstrate that Pin1 strongly stimulates the phosphatase
activity of Ssu72 (Supplementary Information and Supplementary
Fig. 6), consistent with its specificity for the cis configuration.
The active site of Ssu72 is located at the bottom of a narrow groove
(Fig. 2e), one wall of which is formed by the small b-sheet (b2A and
b2B) and the loop linking the two strands (Fig. 2d). This severely limits
the possible conformation of the CTD, ensuring that only the cis
configuration of the pSer-Pro peptide bond can be accommodated
in the active site. In fact, the Thr 4-pSer 5 peptide bond is p-stacked
with the Pro 6-Ser 7 peptide bond (Fig. 2d), suggesting a highly
restrained conformation for the CTD phosphopeptide in this region.
Residues Thr 4, pSer 5 and Pro 6 of the same repeat as well as Tyr 1 of
the following repeat have interactions with the enzyme (Fig. 2d and
Supplementary Information), explaining the preference for pSer 5 by
Ssu72 and consistent with results from earlier biochemical studies on
yeast Ssu72 (ref. 14).
The phosphate group of the peptide is bound deepest in the struc-
ture, having extensive ion-pair and hydrogen-bonding interactions
with the enzyme (Fig. 2d). In addition, the main-chain amide group
of pSer 5 is hydrogen-bonded to the main-chain carbonyl of Lys 43 (in
b2A). The catalytic nucleophile of Ssu72, Cys 12, is located directly
below the phosphate group and can be in the correct position for the
inline nucleophilic attack on the phosphorus atom to initiate the reac-
tion (Supplementary Fig. 7). The side chain of Asp 143 is located 3.5Å
from theOc atomof Ser 5, consistent with its role as the general acid to
protonate the leaving group. There are some conformational changes
in the active-site region of Ssu72, especially for the b2A–b2B loop, on
binding of the CTD phosphopeptide (Supplementary Fig. 7), although
this loop seems to be flexible and can assume different conformations
in the various structures.
In the structures of the binary and ternary complexes, Ssu72 is
bound to the concave face of Symp-N (Fig. 1b). About 950Å2 of the
surface area of each protein is buried in the interface of this complex,
which involves helices a3B–a6B of Symp-N (Fig. 3a and Supplemen-
tary Fig. 1), and helix aE, the following aE–b4 loop, helix aG and
strand b5 of Ssu72 (Supplementary Fig. 3). In addition, residue
Arg 206, at the tip of the long loop connecting helices a4B and a5A
of Symp-N, is also located in the interface (Fig. 3a). Ion-pair, hydrogen-
bonding and hydrophobic interactions make contributions to the
formationof this complex (Supplementary Information). In particular,
the side chains of Val 191 and Phe 193 of Ssu72 (in strand b5) establish
hydrophobic interactionswith those of Lys 185 (a4B) and Ile 251 (a5B)
of symplekin in the centre of this interface (Fig. 3a). In addition, the
side-chain hydroxyl group of Thr 190 (b5) of Ssu72 is hydrogen-
bonded to the side chain of Asn 300 (a6B) of symplekin. The relative















































































































Figure 3 | Structural and biochemical characterizations of the symplekin–
Ssu72 interface. a, Stereo pair showing detailed interactions between
symplekin (in cyan) and Ssu72 (in yellow) in the interface. The molecular
surface of symplekin is also shown (in cyan). Side chains making important
contributions to the interface are shown as stick models. Residues labelled in
red were selected for mutagenesis. b, The activity of Ssu72, measured by the
hydrolysis of pNPP, as a function of the molar ratio of symplekin. TA/VA/FA,
T190A/V191A/F193A mutant of Ssu72 (stimulation by wild-type (WT)
symplekin). Results are shown as means6 s.d. for three independent
experiments. c, Stimulation of the CTD Ser 5 phosphatase activity of Ssu72 by
symplekin. The levels of pSer 5 and total CTD were determined using the H14
and 8WG16 antibodies, respectively. d, Gel-filtration profiles for wild-type
symplekin N-terminal domain alone, wild-type human Ssu72 (full-length)
alone, and a mixture of the two (with Ssu72 present in roughly twofold molar
excess). e, Gel-filtration profiles for wild-type Ssu72 alone, K185A mutant of
symplekin alone, and a mixture of the two.
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the binary and ternary complexes (Supplementary Information and
Supplementary Fig. 8).
The symplekin–Ssu72 interface is located about 25Å from the active
site of Ssu72 (Fig. 1b). However, phosphatase assays measuring the
hydrolysis of a p-nitrophenyl phosphate (pNPP) model substrate11,12
showed that Symp-N stimulated Ssu72 activity (Fig. 3b), and maximal
activation was achieved when the two proteins were at a 1:1 molar
ratio. To assess whether this stimulation also occurs with a natural
substrate, we first used the decamer CTDphosphopeptide in the assay,
monitoring the release of inorganic phosphate, and observed a similar
stimulation (Supplementary Fig. 6). We next prepared a glutathione
S-transferase (GST)–CTD fusion protein that had been phosphorylated
on Ser 2 and Ser 5 with HeLa nuclear extract26. As demonstrated by
western blotting with a pSer 5-specific antibody, Ssu72 dephosphory-
lated this protein on Ser 5, in a manner that was also stimulated by
Symp-N (Fig. 3c). Ssu72 was specific for dephosphorylating pSer 5,
because Ser 2 phosphorylation, as monitored by a pSer 2-specific
antibody, was not affected (data not shown).
Our data indicate that the symplekin–Ssu72 interaction activated
Ssu72 phosphatase activity, probably through stabilization of the
Ssu72 structure and/or an allostericmechanism. This is consistent with
previous studies on the R129A mutant (ssu72-2) of yeast Ssu72, equi-
valent toArg 126 in human Ssu72 (Supplementary Fig. 3). Thismutant
shows a twofold decrease in catalytic activity compared with wild-type
Ssu72 and produces a severe growth defect at the non-permissive tem-
perature16. Arg 126 is far from the active site and is in fact near the
interface with symplekin (Fig. 3a). However, it does not contribute
directly to interactions with symplekin, and the R126A mutation did
not disrupt interaction with Symp-N (data not shown).
To assess the importance of individual residues for the stability of
the symplekin–Ssu72 complex, we introduced mutations in the inter-
face and characterized their effects on the complex byusing gel-filtration
chromatography and phosphatase assays. The presence of wild-type
Ssu72 gave rise to a clear shift in the peak for Symp-N from a gel-
filtration column (Fig. 3d), corresponding to the formation of the
symplekin–Ssu72 complex. Ssu72 was present in twofold molar excess
in this experiment, and only half of this protein was incorporated into
the complex (Fig. 3d), demonstrating a 1:1 stoichiometry for the com-
plex. Mutation of a symplekin residue in the interface, K185A (Fig. 3a),
essentially abolished the interaction with wild-type Ssu72 (Fig. 3e), and
mutation of three Ssu72 residues in the interface, T190A/V191A/
F193A, abolished the interaction with wild-type symplekin. The chro-
matographic behaviour of the mutants alone was similar to that of the
wild-type protein (Fig. 3e), suggesting that themutations did notdisrupt
the structure of the proteins. This was also confirmed by the crystal
structure of the K185A mutant (data not shown). Consistent with the
gel-filtration data, the symplekin K185A mutant failed to stimulate
Ssu72 phosphatase activity, and the T190A/V191A/F193A mutant of
Ssu72 could not be stimulated by wild-type Symp-N (Fig. 3b).
Wenextwished to assess the functional importance of the symplekin–
Ssu72 interaction with respect to 39-end formation. Given the roles of
their yeast counterparts in both transcription and polyadenylation, we
used a transcription-coupled 39-end processing assay27. HeLa nuclear
extract was preincubated with increasing concentrations of Symp-N,
which led to a pronounced inhibition of polyadenylation (Fig. 4a),
similar to an effect observed earlier with the yeast Pta1 N-terminal
domain in a transcription-independent assay9. Transcription, as mea-
sured by the accumulation of unprocessed pre-mRNA,was not affected
(Fig. 4b). RNase protection assays showed that 39-end cleavagewas also
not affected (Supplementary Fig. 9), indicating that Symp-N affects
only the polyadenylation stepof 39-end formation. Inclusionof purified
Ssu72 during the preincubation with Symp-N blocked the inhibition,
whereas Ssu72 alone had no effect (Fig. 4c). The K185A mutation in
Symp-N abolished this inhibitory effect, whereas the T190A/V191A/
F193A mutant of Ssu72 failed to overcome the inhibition by wild-
type Symp-N (Fig. 4c). These results provide strong evidence that the
inhibitory effect of Symp-N reflects its interaction with Ssu72, and thus
implicates Ssu72 in mammalian 39-end processing. In contrast with
studies in yeast7,9, the catalytically inactive C12Smutant of Ssu72 failed
to overcome this inhibition (Fig. 4c), and Symp-N had no detectable
effect on transcription-independent polyadenylation (Fig. 4d, and data
not shown). Together, these results indicate that Ssu72 phosphatase
activity is required for polyadenylation of pre-mRNAs, but only when
processing is coupled to transcription.
Our finding that a CTD phosphopeptide is bound to Ssu72 with the
pSer-Pro peptide bond in the cis configuration indicates the existence of a
novel CTD conformation. Although Ssu72 has beenwell studied in yeast
and has functions in transcription and 39-end processing, essentially
nothing was known about its mammalian counterpart. In fact, whereas
the yeast enzyme is a stable componentof thepolyadenylationmachinery
and is required for processing, mammalian Ssu72 has not been found
associated with polyadenylation factors and was not detected in a recent
proteomic analysis of the assembled polyadenylation complex28. Con-
sistent with this, our results provide evidence that in mammals Ssu72


























































































Figure 4 | Functional characterization of the symplekin–Ssu72 interaction.
a, Transcription-coupled polyadenylation is inhibited in a dose-dependent
fashion by symplekin N-terminal domain. Transcription-processing was
performed in HeLa nuclear extract; RNAs were purified and separated into
poly(A)2 and poly(A)1 fractions, and resolved by denaturing PAGE. Positions
of unprocessed ‘run-off’ RNA (pre-mRNA) and cleaved and polyadenylated
RNA (poly(A) RNA) are indicated. b, Symplekin N-terminal domain does not
inhibit transcription. Poly(A)2 RNAs (2%) from the transcription-coupled
polyadenylation assays in the presence of increasing concentrations of
symplekin N-terminal domain are shown. c, Ssu72 overcomes the inhibition of
transcription-coupled polyadenylation by symplekin. The effects of the K185A
mutant of symplekin and the C12S and T190A/V191A/F193A (TA/VA/FA)
mutants of Ssu72 on polyadenylation are also shown. d, Polyadenylation of
SV40 late pre-mRNA, uncoupled to transcription, is not inhibited by symplekin
N-terminal domain.
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transcription. A parsimonious model is that symplekin recruits Ssu72 to
the transcription complex and activates its phosphatase activity, which
promotes polyadenylation. Conceivably, this occurs by facilitating the
recruitment of poly(A) polymerase, known for many years to be only
weakly associated with other 39-end processing factors28,29, to the com-
plex. Given that the CTD is necessary for efficient 39-end formation in
mammalian cells26,30, and that CTD pSer 5 is the only known target of
Ssu72, CTD pSer 5 dephosphorylation may well be important in facili-
tating polyadenylation during transcription.
METHODS SUMMARY
Crystallography. The N-terminal domain of human symplekin and full-length
human Ssu72 were overexpressed separately in Escherichia coli and purified. The
symplekin–Ssu72 complex was purified by gel filtration of a mixture of the two
proteins. Crystals were obtained by the sitting-drop vapour-diffusion method, and
the structuresweredeterminedby the selenomethionyl single-wavelength anomalous
diffraction method and the molecular replacement method.
In vitro transcription-coupled polyadenylation assay. Transcription-coupled
polyadenylation was performed with a DNA construct containing GAL4-binding
sites upstream of the adenovirus E4 core promoter and SV40 late poly(A) site
downstream. Recombinant symplekin and Ssu72 proteins were preincubated
with HeLa nuclear extract before transcription was started by adding the DNA
template and purified GAL4–VP16. RNA products were purified, separated into
nonpolyadenylated and polyadenylated fractions and analysed on 5% denaturing
gel. Radioactivity was detected with a PhosphorImager. Assays were repeated
multiple times with consistent results.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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Protein expression and purification.Residues 30–395 of human symplekinwere
subcloned into the pET28a vector (Novagen). The recombinant protein carries a
hexahistidine tag at the N terminus. The plasmids were transformed into E. coli
BL21(DE3) Star cells. After induction with 0.5mM isopropyl b-D-thiogalactoside,
the cells were allowed to grow at 20 uC for 14–16 h, collected by centrifugation, and
lysed by sonication. Soluble symplekin was purified by Ni21-nitrilotriacetate
(Qiagen) and gel-filtration (Sephacryl S-300; GE Healthcare) chromatography.
Purified protein was concentrated to 15mgml21 in a buffer containing 20mM
Tris-HCl pH8.5, 200mMNaCl, 10mMdithiothreitol (DTT) and 5% (v/v) glycerol,
flash-frozen in liquid nitrogen and stored at280 uC. The N-terminal His-tag was
not removed for crystallization.
The selenomethionyl protein sample was produced in E. coli B834(DE3) cells,
and the bacteria were grown in defined LeMaster medium supplemented with
selenomethionine31. The purification procedure was the same as for the native
protein.
To prepare the symplekin–Ssu72 complex, residues 30–360 of human symplekin
and full-length human Ssu72 were cloned separately into the pET28a vector. Both
proteins carried a hexahistidine tag at the N terminus and were purified separately
by Ni21-nitrilotriacetate (Qiagen) and gel-filtration (Sephacryl S-300; GE
Healthcare) chromatography. The purified proteins were then mixed, with Ssu72
present in slightmolar excess (1:1.2molar ratio), and the symplekin–Ssu72complex
was purifiedby gel-filtration chromatography. Purifiedproteinwas concentrated to
10mgml21 in a buffer containing 20mMTris-HCl pH8.5, 200mMNaCl, 10mM
DTT and 5% (v/v) glycerol, flash-frozen in liquid nitrogen and stored at280 uC.
Protein crystallization. Crystals of symplekin (residues 30–395) were obtained
with the sitting-drop vapour-diffusion method at 20 uC. The reservoir solution
contained 50mM Bis-Tris pH6.5, 40mM ammonium sulphate and 40% (v/v)
pentaerythritol ethoxylate (15/4 EO/OH). The crystals belong to space group
P21, with unit cell parameters of a5 41.6Å, b5 63.0Å, c5 62.3Å and
b5 90.6u. There is one symplekin molecule in the asymmetric unit.
Crystals of the symplekin–Ssu72 complex were obtained with the sitting-drop
vapour-diffusion method at 20 uC. The reservoir solution contained 0.32M
ammonium sulphate and 26% (w/v) PEG3350. The crystals belong to space group
P21212, with unit cell parameters of a5 99.4Å, b5 113.6Å and c5 59.1Å. There
is one symplekin–Ssu72 complex in the asymmetric unit.
Crystals of the symplekin–Ssu72–CTD phosphopeptide ternary complex were
obtained with the sitting-drop vapour-diffusion method at 20 uC. The reservoir
solution contained 1.6M ammonium chloride and 27% (w/v) PEG3350. Sodium
potassium tartrate (10mM)was included as an additive in the drop. These crystals
of the symplekin–Ssu72 binary complex were soaked overnight in a solution
containing 30mM CTD phosphopeptide, 25% (w/v) PEG3000 and 100mM
Tris-HCl pH8.5 at 20 uC. The crystal belongs to space group P21, with unit cell
parameters of a5 67.0Å, b5 97.6Å, c5 105.0Å and b5 98.7u. There are two
copies of the symplekin–Ssu72 complex in the asymmetric unit. The CTD phos-
phopeptide was observed in only one of the Ssu72 molecules, and a phosphate is
bound in the active site of the other Ssu72 molecule. We found that commercial
PEG3350 contains some phosphate (about 1mM) as a contaminant.
The crystals were cryoprotected by the reservoir solution, supplemented with
25% (v/v) ethylene glycol if necessary, and flash-frozen in liquid nitrogen for data
collection at 100K.
Data collection and structure determination. The structure of symplekin alone
was determined by the selenomethionyl anomalous diffractionmethod32. A single-
wavelength anomalous diffraction (SAD) data set to 2.0Å resolution was collected
on a SeMet-substituted crystal at beamline 9-2 of the Stanford Synchrotron
Radiation Laboratory. A native reflection data set to 1.4Å resolution was collected
at the same beamline. Thediffraction datawere processed and scaledwith theHKL
package33. The data processing statistics are summarized in SupplementaryTable 1.
The Se atoms were located with the program BnP34, and the reflections were
phased with the program Solve35. Most of the residues were built automatically by
the program Resolve, and the model was completed by manual building with the
programs O36 and Coot37. The structure refinement was performed with the
programs CNS38 and Refmac39.
The structure of the symplekin–Ssu72 complexwas determinedby themolecular
replacement method, with the program COMO40. A native reflection data set to
2.5Å resolution was collected at the X4C beamline of the National Synchrotron
Light Source. The structures of symplekin and Drosophila Ssu72 (PDB ID 3FDF)
were used as the search models.
A native reflection data set to 2.4Å resolution was collected at the X29 beamline
on the symplekin–Ssu72–CTD phosphopeptide ternary complex.
Symplekin–Ssu72 interactions. Symplekin and Ssu72 mutants were made with
the QuikChange kit (Stratagene) and verified by sequencing. The mutant proteins
were expressed and purified by following the same protocol as that for the wild-
type protein.
Analytical gel-filtration experiments were carried out on a Superose-12 10/30
column (GE Healthcare), with a buffer containing 20mM Tris-HCl pH7.5 and
200mMNaCl. Symplekin (210mg) andSsu72 (380mg)weremixed anddiluted to a
final volume of 500ml with the gel-filtration buffer. The mixture was incubated on
ice for 1 hbeforebeing loadedon the column.Theproteinswere also run separately
on the column to determine their migration behaviour alone.
Ssu72 CTD peptide phosphatase assays. Reaction mixtures (50ml) containing
20mMTris-HCl pH7.5, 150mMNaCl, 5mMDTT, the indicated amount ofCTD
phosphopeptide, Ssu72 and symplekinwere incubated at 37 uC. Time-point samples
were taken and quenched by the addition of 0.5ml of malachite green reagent
(BIOMOLResearch Laboratories). Phosphate release was determined bymeasuring
A620 and comparing it with a phosphate standard curve.
To study the effect of Pin1 on Ssu72, reaction mixtures (50ml) containing
50mMTris-HCl pH7.5, 50mMNaCl, 5mMDTT, 500mMCTDphosphopeptide
and the indicated amount of Ssu72 and GST–Pin1 were incubated at 10 uC.
Phosphate release was determined with the malachite green reagent.
Ssu72 GST–CTD phosphatase assays. GST–CTD fusion protein was expressed,
purified and phosphorylated in vitro as described previously41. GST–CTD phos-
phatase assays were performed in a total volume of 10ml containing 50mM Tris-
HClpH7.9, 100mMKCl, 12.5mMMgCl2, 0.5mMEDTA,5%(v/v)glycerol and the
indicated amount of phosphorylated GST–CTD as a substrate, Ssu72, symplekin or
their mutants. Reactions were incubated for various durations at 37 uC, stopped by
theaddition of SDS loading buffer and resolved by8%SDS–PAGE. pSer 2 andpSer 5
levels were detected by western blot with 3E10 (ref. 42) and H14 (Covance)
antibodies, respectively.
In vitro transcription-coupled polyadenylation assay.TheDNA construct used
for the transcription-coupled polyadenylation assay contained GAL4-binding
sites upstream of an E4 core promoter and an SV40 late poly(A) site downstream.
Transcription-coupled polyadenylation was performed at 30 uC for 1 h in 20-ml
reaction mixtures containing 10ml of nuclear extract, 100ng of Gal4–VP16,
recombinant proteins (symplekin and Ssu72), 12mM HEPES pH7.9, 500ng of
the DNA templates, 0.5mM each of ATP, GTP and CTP, 15mMunlabelled UTP,
10mCi of [a-32P]UTP, 4mM MgCl2, 20mM creatine phosphate (di-tris), 2.4%
PEG8000, 12% glycerol, 60mMKCl, 0.12mMEDTA, 0.12mMDTT and 0.3mM
phenylmethylsulphonyl fluoride. Recombinant symplekin and Ssu72 proteins
were preincubated with nuclear extract (30min at 23 uC) before transcrip-
tion was started by adding the DNA templates. The reaction was stopped by
adding proteinaseK. RNA products were separated into non-polyadenylated
and polyadenylated fractions by oligo(dT) selection; thereafter 2% of non-
polyadenylated and 100% of polyadenylated fractions were analysed on 5%
denaturing gel. Radioactivity was detected with a PhosphorImager.
RNase protection assay. To make the probe, pG3SVL-A was linearized with SalI
and transcribed with T7 RNA polymerase (Promega) for 2 h at 37 uC, uniformly
labelled with [a-32P]UTP. The RNA was gel purified and resuspended in hybridiza-
tion buffer containing 40mM PIPES pH6.4, 400mMNaCl, 1mM EDTA and 80%
(v/v) formamide.
Transcription-coupled polyadenylation was performed as mentioned above
except that 0.5mM each of ATP, GTP, UTP and CTP, but no [a-32P]UTP, were
used in the reactionmixture. The RNA/DNAmixture was resuspended in 20ml of
TurboDNase buffer (Ambion) with 1U of TurboDNase (Ambion) and incubated
for 1 h at 37 uC to remove the DNA template. The remaining RNA products were
hybridized overnight with the probe (53 105 c.p.m.) at 42 uC. Each reaction was
then incubated for 45 min with 14mg of RNase A and 0.7mg of RNase T1 at 30 uC.
The final RNA products were resolved on a 10% denaturing gel. Radioactivity was
detected with a PhosphorImager.
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Comparison of Ssu72 with other CTD phosphatases 
The structure of Ssu72 has a different backbone fold compared to other CTD 
phosphatases with known structures, such as Scp1 and Fcp1. Scp1 prefers pSer5 CTD as 
the substrate 43, while Fcp1 prefers pSer2 (ref. 44). The catalysis of both enzymes requires 
Mg2+, in contrast to Ssu72. The active sites of these enzymes have pockets that can 
accommodate the trans configuration of the CTD. In fact, the structure of Scp1 in 
complex with a CTD phosphopeptide shows that the cis configuration is incompatible 
with its active site. Therefore, Ssu72 and Scp1 may have mutually exclusive preferences 
for their CTD substrate.  
 
Pin1 stimulates phosphatase activity of Ssu72 
The phosphatase activity of Ssu72 towards the 10-mer CTD phosphopeptide was 
monitored through the release of inorganic phosphate. 31P NMR experiments suggest that 
the cis configuration of the peptide is present in roughly 20% abundance, similar to 
results on other phosphopeptides (~10%) 45. Pin1 is expected to facilitate the trans-cis 
isomerization and thereby increases the apparent phosphatase activity of Ssu72 towards 
this peptide. To demonstrate this simulation, we incubated the phosphopeptide (500 µM 
concentration) with Ssu72 (200 µM), and determined the effect of 10 µM Pin1 (purified 
as a GST-fusion protein) on this reaction. The reactions were carried out at 10°C to 
reduce the spontaneous isomerization between the two configurations. The results of the 
assays show a 4-fold stimulation of the phosphatase activity of Ssu72 (Supplementary 
Fig. 6), consistent with its specificity for the cis configuration of the substrate.  
 
Interactions between the CTD phosphopeptide and Ssu72 
The phosphate group of the pSer5 residue is recognized by bi-dentate ion-pair 
interactions with the side chain of Arg18 and extensive hydrogen-bonding interactions 
with the main-chain amides of residues 13-18 (in the β1-αA loop) (Fig. 2d). The main-
chain amide of pSer5 is hydrogen-bonded to the main-chain carbonyl of Lys43 (β2A). 
The side chain of Pro6 is positioned near two hydrophobic residues, Pro45 (β2A-β2B 
loop) and Met84 (αD helix). One face of the Tyr1’ residue from the next heptad repeat is 
positioned against residues Ala48-Pro49 (β2A-β2B loop), while the other face is 
exposed. The main-chain amide of this Tyr residue may be hydrogen-bonded to the side 
chain of Thr4. In contrast, residues Pro3 and Ser7 do not have interactions with the 
enzyme. In addition, residues of the phosphopeptide that are disordered in the current 
structure, SY1S2 and S2’, probably do not have strong interactions with Ssu72 either.  
 
Interface between symplekin and Ssu72 
The interface between symplekin N-terminal domain and Ssu72 involves ion-pair, 
hydrogen-bonding, and hydrophobic interactions. The ion-pair interactions include those 
between the side chains of Lys185 (symplekin) and Glu127 (Ssu72), Lys299 and Glu113 
and Asp117, Arg206 (in the long loop in symplekin) and Glu129, and Lys127 and 
Glu169 (Fig. 3a). The hydrogen-bonding interactions include those between the side 
chains of Asn300 (symplekin) and Thr190 (Ssu72), and Ser292 and Glu180. A large 
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number of residues make important contributions to the surface area burial in this 
interface, and they are highlighted in Supplementary Fig. 1 for symplekin and 
Supplementary Fig. 3 for Ssu72. Residues with greater than 50 Å2 surface area burial in 
symplekin are Leu131, Lys185, Arg206, Ile251, Ser292, Ser296, and Lys299, and those 
in Ssu72 are Glu129, Cys131, Glu169, Asn170, Leu188, and Phe193.  
In the crystals of the binary and ternary complexes, a second possible interface 
exists between symplekin and Ssu72, where Ssu72 is bound to the convex face of the N-
terminal domain (Supplementary Fig. 10). The amount of buried surface area in this 
interface is smaller, about 830 Å2. Three hydrophobic residues, Leu150 and Phe153 of 
Ssu72 and Met116 of symplekin, are located in the center of this interface 
(Supplementary Fig. 10). Our mutagenesis studies, on M116A mutant in symplekin and 
L150A/F153A mutant in Ssu72, showed however that this interface is not important for 
symplekin-Ssu72 interactions. Nonetheless, the structural observations provide additional 
evidence that the surface of symplekin may be capable of interacting with many different 
protein partners, in agreement with the scaffold function of this protein. 
 
Conformational plasticity in the symplekin-Ssu72 complex 
The relative positions of symplekin N-terminal domain and Ssu72 show some 
degree of variation among the structures that we have studied. These include the ternary 
complex, a binary complex in the same space group (P21) as the ternary complex, and a 
binary complex in a different space group (P21212). There are two copies of the 
complexes in the monoclinic space groups, affording a total of five complexes for 
comparison (Supplementary Fig. 8). Clear differences in the position of symplekin 
relative to Ssu72 are observed in the two ternary complexes. Interestingly, only one of the 
two complexes contained the CTD phosphopeptide in the Ssu72 active site, while the 
other complex in the same crystal contained only a phosphate group, although neither 
active site was directly involved in crystal packing. This suggests that the position of 
symplekin N-terminal domain might allosterically affect binding in the active site of 
Ssu72, which may be consistent with our observation of the stimulatory effect of 
symplekin on Ssu72.  
There are no major conformational changes in the N-terminal domain of symplekin 
upon the formation of the complex with Ssu72 (Supplementary Fig. 11). The rms 
distance for equivalent Cα atoms in the structures of the N-terminal domain alone and in 
the complex is 1.0 Å, although the arc for the N-terminal domain has a slightly higher 
curvature in the complex with Ssu72. Similarly, no major conformational differences are 
observed between the structure of human Ssu72 in the complex with symplekin and that 
of Drosophila Ssu72 alone (PDB entry 3FDF, Supplementary Fig. 7). The rms distance 
for equivalent Cα atoms of the two structures is 1.0 Å, and the two proteins share 61% 
amino acid sequence identity (Supplementary Fig. 3). 
 
Implications for the structure of the Pta1-Ssu72 complex 
Residues that make important contributions to the symplekin-Ssu72 interface are 
generally conserved or show conservative variations among symplekin (Supplementary 
Fig. 1) and Ssu72 (Supplementary Fig. 3) homologs. While Pta1 has much weaker 
sequence homology with symplekin, some of the symplekin residues in the interface with 
Ssu72 may be conserved in Pta1. For example, three consecutive predicted helices in 







Pta1 (between residues 90 and 180) each contains a highly conserved Lys residue in the 
middle (Supplementary Fig. 2), one of which may be equivalent to the Lys185 residue in 
symplekin. At the same time, it could also be possible that the exact binding mode of 
yeast Ssu72 to Pta1 may be somewhat different from that observed here for the human 
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Table 1. Data collection and refinement statistics 
 





Data collection    
Space group P21 P21212 P21 
Cell dimensions    
    a, b, c (Å) 41.6, 63.0, 62.3 99.4, 113.6, 59.1 67.0, 97.6, 105.0 
    α, β, γ  (°)  90, 90.6, 90 90, 90, 90 90, 98.7, 90 
Resolution (Å) 30–1.4 (1.5–1.4)* 30–2.5 (2.6–2.5) 30–2.4 (2.5–2.4) 
Rmerge 2.9 (49.2) 6.7 (30.6) 7.8 (40.5) 
I/σI 40.4 (1.7) 15.7 (3.1) 11.8 (2.4) 
Completeness (%) 99 (95) 100 (99) 100 (99) 
Redundancy 3.6 (2.5) 4.1 (3.6) 3.3 (3.3) 
    
Refinement    
Resolution (Å) 30–1.4 30–2.5 30–2.4 
No. reflections 59,384 22,566 49,442 
Rwork/ Rfree 16.0 / 19.2 21.1 / 26.6 18.4 / 24.1 
No. atoms    
    Protein 2,409 4,014 8,078 
    Ligand/ion 4 5 54 
    Water 332 76 250 
B-factors    
    Protein 15 41 36 
    Ligand/ion 17 33 44 
    Water 35 22 32 
R.m.s deviations    
    Bond lengths (Å)  0.015 0.017 0.016 
    Bond angles (º) 1.5 1.7 1.6 
One crystal was used for the collection of each data set.  
*Highest resolution shell is shown in parenthesis.  
 
 










Fig. 1. Sequence alignment of the N-terminal domain of symplekin. The 
secondary structure elements in the structure of human symplekin are 
indicated (S. S.). Residues in human symplekin that have less than 
25% exposed surface area are colored in magenta, and those not 
observed in our structure are shown in italic. The red dots highlight 
those residues in the interface with Ssu72 (with more than 15 Å2 
contribution to the surface area burial).  
 






   
 
 
Fig. 2. Sequence alignment of the putative N-terminal domain of fungal 
Pta1 homologs. The predicted helices are indicated. The low sequence 
conservation with symplekin makes it difficult to produce a reliable 
alignment of their sequences together, and therefore two separate 
alignments are shown.  
 






   
 
 
Fig. 3. Sequence alignment of eukaryotic Ssu72. The catalytic 
nucleophile, Cys12, is shown in red, and residues identical among the 
sequences are highlighted in magenta. The red dots highlight those 
residues in the interface with symplekin.  










Fig. 4. (Top). Structure of the C12S mutant of Ssu72 in complex with a 
CTD phosphopeptide. (Bottom). Overlay of the structures of wild-type 
human Ssu72 (in yellow) and the bovine low-molecular-weight 
phosphotyrosine protein phosphatase (in gray) 46. The active site 
residues of Ssu72 and a sulfate ion are shown as stick models. Red 
arrows point to unique structural features of Ssu72. Produced with the 
program PyMOL (www.pymol.org).  
 










Fig. 5. Overlay of the bound conformations of CTD peptides to various 
proteins, Ssu72 (green), CTD Ser5 phosphatase Scp1 (cyan) 43, WW 
domain of Pin1 prolyl isomerase (yellow) 47, and RNA 
guanylyltransferase Cgt1 (pink) 48. The direction of the peptide 
backbone in the Ssu72 complex is indicated in red, while that of the 
others is in black, going in the opposite direction.  
 










Fig. 6. (Left) Pin1 stimulates the phosphatase activity of Ssu72. The 
reaction velocity of Ssu72 towards the 10-mer CTD phosphopeptide 
was determined in the absence and presence of Pin1, at 10°C to reduce 
spontaneous cis-trans isomerization. A four-fold stimulation was 
observed. (Right) Symplekin N-terminal domain stimulates the 
phosphatase activity of Ssu72 towards the 10-mer CTD peptide. In 
both assays, the release of inorganic phosphate was monitored, with 
the BIOMOL reagent.  
 










Fig. 7. (Top). Overlay of the structure of human Ssu72 in the complex 
with symplekin and CTD phosphopeptide (in yellow) with that of 
Ssu72 in complex with symplekin (in gray). A change in the side chain 
rotamer of Cys12 will bring it into the correct location for catalysis, as 
seen with Ser12. (Bottom). Overlay of the structure of human Ssu72 in 
the complex with symplekin (in yellow) with that of Drosophila Ssu72 
alone (PDB entry 3FDF, in gray).  
 










Fig. 8. Overlay of the structures of symplekin-Ssu72 complexes. The 
ternary complex is shown in cyan for symplekin, yellow for Ssu72 and 
green for the CTD phosphopeptide. The binary complex in the same 
crystal (with a phosphate in the Ssu72 active site) is shown in pink. 
The two complexes in the other P21 crystal are shown in gray, and the 
binary complex in the P21212 crystal is shown in orange. The overlay 
is based on the structure of Ssu72 only.  
 










Fig. 9. Symplekin N-terminal domain does not affect transcription-
coupled 3’-end cleavage. RNase protection was carried out after 
transcription-coupled polyadenylation. Positions of the unprocessed 
RNA (pre-mRNA, 140nt) and the cleaved product (80nt) are indicated.  
 









Fig. 10. Another possible symplekin-Ssu72 interface in the crystal of the 
complex. Symplekin is shown in cyan, Ssu72 in yellow. Ssu72 is 
bound to the convex face of the symplekin structure. The side chains 
of Leu150 and Phe153 in Ssu72 and Met116 in symplekin are shown 
as stick models.  
 










Fig. 11. Overlay of the structure of the N-terminal domain of symplekin 
alone (in gray) and in complex with Ssu72 (in cyan). The panel on the 

















Chapter III: An unexpected binding mode for a Pol II CTD peptide phosphorylated at Ser7 







An unexpected binding mode
for a Pol II CTD peptide
phosphorylated at Ser7
in the active site
of the CTD phosphatase Ssu72
Kehui Xiang, James L. Manley, and Liang Tong1
Department of Biological Sciences, Columbia University, New
York, New York 10027, USA
Ssu72, an RNA polymerase II C-terminal domain (CTD)
phospho-Ser5 (pSer5) phosphatase, was recently reported
to have pSer7 phosphatase activity as well. We report here
the crystal structure of a ternary complex of the N-ter-
minal domain of human symplekin, human Ssu72, and
a 10-mer pSer7 CTD peptide. Surprisingly, the peptide is
bound in the Ssu72 active site with its backbone running
in the opposite direction compared with a pSer5 peptide.
The pSer7 phosphatase activity of Ssu72 is ~4000-fold
lower than its pSer5 phosphatase activity toward a peptide
substrate, consistent with the structural observations.
Supplemental material is available for this article.
Received June 18, 2012; revised version accepted August 28,
2012.
Transcription of mRNA and noncoding RNA in eukary-
otes is carried out by RNA polymerase II (Pol II), the
activity of which is regulated in part by the phosphory-
lation state of the C-terminal domain (CTD) of its largest
subunit (Komarnitsky et al. 2000; Schroeder et al. 2000;
Meinhart et al. 2005; Phatnani and Greenleaf 2006;
Buratowski 2009; Kim et al. 2009, 2010; Mayer et al.
2010; Tietjen et al. 2010). The CTD contains the consen-
sus heptapeptide repeat Tyr1–Ser2–Pro3–Thr4–Ser5–
Pro6–Ser7 (YSPTSPS), and phosphorylation of Ser5 and
Ser2 has long been recognized for its importance in
transcription and coupled RNA processing events. Phos-
phorylation of Ser7 is involved in snRNA transcription
and 39 end processing (Chapman et al. 2007; Egloff et al.
2007), and phosphorylation of Thr4 has been linked to
histone mRNA 39 end processing (Hsin et al. 2011). CTD
kinases and phosphatases control the phosphorylation
state of the CTD and thereby regulate Pol II activity. For
example, Fcp1 preferentially dephosphorylates pSer2 over
pSer5 (Hausmann and Shuman 2002; Hausmann et al.
2004; Ghosh et al. 2008), while Ssu72 is a pSer5 phospha-
tase (Krishnamurthy et al. 2004; Hausmann et al. 2005).
Both are essential for viability in yeast.
Recently, it was reported that Ssu72 also has pSer7
phosphatase activity (Bataille et al. 2012; Zhang et al.
2012). However, such an activity for Ssu72 is unexpected
from a structural perspective. Ssu72 recognizes the cis
configuration of the pSer5–Pro6 peptide bond as a pSer5
phosphatase (Xiang et al. 2010; Werner-Allen et al. 2011).
In comparison, pSer7 is followed by Tyr1 in the next
repeat of the CTD (designated Tyr19). If Ssu72 were to
bind the pSer5 and pSer7 substrates in the same way, the
pSer7–Tyr19 peptide bond would need to be in the cis con-
figuration, which is much less favorable energetically.
Moreover, the bulkier Tyr side chain would be placed in
the binding site for the Pro6 residue in the pSer5 sub-
strate, which would clash with the enzyme.
Results and Discussion
To understand the structural basis for how Ssu72 func-
tions as a pSer7 phosphatase, we determined the crystal
structure at 2.2 A˚ resolution of a ternary complex of a
human symplekin N-terminal domain (NTD, residues
30–360), human Ssu72 (C12S mutant), and a 10-mer CTD
peptide phosphorylated at Ser7 (Ser2–Pro3–Thr4–Ser5–
Pro6–pSer7–Tyr19–Ser29–Pro39–Thr49, with the prime in-
dicating the next repeat of the CTD) (Fig. 1A). Symplekin
is a scaffold protein in the pre-mRNA 39 end processing
machinery (Takagaki and Manley 2000) and is known to
interact with and enhance the activity of Ssu72 (Xiang
et al. 2010). It was included here because it is important
for the crystallization of human Ssu72 (Xiang et al. 2010).
Crystals of the symplekin NTD–Ssu72 binary complex
were soaked with the phosphopeptide, following the
same protocol as used earlier for the pSer5 peptide (Xiang
et al. 2010). Electron density was observed for most of
the peptide based on the crystallographic analysis, except
for one residue at either end of the peptide (Fig. 1B). In
addition, the side chain of Tyr19 has weak electron
density.
Surprisingly, the pSer7 peptide is bound in the Ssu72
active site with its peptide backbone running in the
opposite direction compared with the pSer5 peptide
(Fig. 1C). As a result, the binding sites for Pro6 and pSer7
are equivalent to those for Pro6 and pSer5 in the pSer5
peptide (Xiang et al. 2010). Residues Ser5–Pro6–pSer7–
Tyr19 assume the conformation of a type I b reverse turn,
so that the overall shapes of the pSer7 and pSer5 peptides
are similar when bound to Ssu72 (Fig. 1C). However,
such a turn is wider than the cis proline structure, and a
difference was observed in the conformation and position
of Pro6 in the two peptides. On the other hand, the Pro6–
pSer7 peptide bond and, in fact, all of the peptide bonds in
the pSer7 peptide are in the trans configuration. The
Tyr19 residue in the pSer5 substrate is important for
phosphatase activity (Hausmann et al. 2005) and shows
interactions with Ssu72 (Fig. 1D; Xiang et al. 2010).
Equivalent interactions are absent in the pSer7 substrate
complex (Fig. 1D).
Recognition of both orientations of peptide substrates
or ligands has rarely been observed with other proteins.
Reported examples include the SH3 domain (Feng et al.
1994; Lim et al. 1994), stromelysin-1 (Becker et al. 1995),
thioredoxin (Qin et al. 1996), and the adaptor protein SspB
of the AAA+ protease ClpXP (Levchenko et al. 2005). As
far as we are aware, this is the first time that a protein
phosphatase has been shown to bind both orientations of
its peptide substrate.
[Keywords: RNA polymerase; protein phosphatase; protein structure]
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Figure 1. The Pol II CTD pSer7 peptide has a novel binding mode in the active site of Ssu72. (A) Schematic drawing of the structure of the
ternary complex of the human symplekin NTD (cyan), human Ssu72 (C12S mutant; yellow), and the pSer7 CTD peptide (green). (B) Omit 2Fo !
Fc electron density for the pSer7 peptide at 2.2 A˚ resolution, contoured at 0.8s. (C) Overlay of the binding modes of the pSer7 peptide (in green)
and the pSer5 peptide (in gray) (Xiang et al. 2010) in the active site of Ssu72. The directions of the peptide backbone are indicated by the arrows.
(D) Overlay of the active site region of Ssu72 in the pSer7 complex (yellow) and the pSer5 complex (in gray). (E) Close-up of the active site region
showing the structural differences in the pSer residues and Asp143. All of the structure figures were produced with PyMOL (http://
www.pymol.org).
Xiang et al.






The pSer7 residue is anchored in the catalytic site and
shows interactions with Ssu72 similar to those of the
pSer5 residue (Fig. 1D; Xiang et al. 2010). Most of the
Ssu72 residues in the active site have the same confor-
mation in the pSer7 and pSer5 peptide complexes. One
notable difference is in the side chain of Asp143, the
general acid of the phosphatase reaction. The oxygen
atom that should donate a proton to the leaving group (Og
of Ser7) is instead hydrogen-bonded to the main chain
amide of Ser7 (Fig. 1E). In contrast, such a hydrogen bond
is not possible with the pSer5 substrate, as the pSer5–Pro6
peptide bond does not have an amide hydrogen. More-
over, the Cb–Og bond of Ser7 is at a right angle to the
Asp143 side chain (Fig. 1E), possibly due to the reversal of
the backbone direction, and therefore the Og atom may
not be in the optimal conformation for receiving the
proton from Asp143. Both of these differences may be
detrimental for the phosphatase activity with the pSer7
substrate.
To understand how Ssu72 distinguishes between pSer2,
pSer5, and pSer7 in the same CTD repeat, we determined
the crystal structure at 2.0 A˚ resolution of another
ternary complex using a 10-mer CTD peptide phosphor-
ylated at all three positions, Ser70–Tyr1–pSer2–Pro3–Thr4–
pSer5–Pro6–pSer7–Tyr19–Ser29. The structure reveals bind-
ing of pSer5 in the catalytic site, while there is no
evidence for pSer7 binding into this site (Fig. 2A). Instead,
the phosphate group on Ser7 is exposed to the solvent,
having no interactions with Ssu72 (Fig. 2B). The phos-
phate group on Ser2 may have ionic interactions with the
side chain of Arg114 (Fig. 2B), although the electron
density for pSer2 is rather weak (Fig. 2A). Overall, the
binding mode of this triply phosphorylated peptide is
similar to that of the pSer5 peptide reported earlier (Fig.
2B; Xiang et al. 2010). A conformational difference in the
Pro3 residue of the peptide was observed, possibly linked
to the interaction of pSer2 with the enzyme. We used
another peptide with pSer7 in the center, Ser2–Pro3–Thr4–
pSer5–Pro6–pSer7–Tyr19–pSer29–Pro39–Thr49–Ser59, and the
observed electron density at 2.6 A˚ resolution was also
consistent with pSer5 binding in the active site (data not
shown). These observations indicate that Ssu72 prefers the
binding of pSer5 and suggest that Ssu72 has higher affinity
for pSer5 in the active site than for pSer7. This may also be
detrimental for the phosphatase activity with the pSer7
substrate.
We next characterized the pSer7 phosphatase activity
of Ssu72 using in vitro assays. We first used an assay that
monitored the release of free phosphate from CTD
phosphopeptides, which we previously used successfully
with the pSer5 peptide (Xiang et al. 2010). Very low
activity was observed in this assay using the 10-mer
pSer7 peptide as substrate. Appreciable phosphate pro-
duction was observed only after overnight incubation of
purified His-tagged Ssu72 (Supplemental Fig. 1) with the
phosphopeptide (40 mMphosphate was released after 12 h
of incubation of 200 mM Ssu72 with 2 mM peptide at
room temperature). The low activity did not appear to be
affected by the presence of the symplekin NTD (results
not shown). Parallel experiments with the 10-mer pSer5
peptide (Xiang et al. 2010) showed that the pSer5 phos-
phatase activity was ;4000-fold higher than the pSer7
phosphatase activity (160 mM phosphate was released
after 45 min of incubation of 5 mM Ssu72 with 1 mM
peptide at room temperature) (Fig. 3A, left panel). As
a comparison, purified yeast Fcp1 (Supplemental Fig. 1)
displayed high activity with both the pSer5 and pSer7
peptides (Fig. 3A, right panel). While the physiological
role of Fcp1 in pSer7 dephosphorylation is unclear (e.g.,
see Bataille et al. 2012), this result at a minimum in-
dicates that the pSer7 peptide used in our assays can be
effectively dephosphorylated in vitro, strengthening the
conclusion that Ssu72 activity toward this peptide sub-
strate is low.
We next tested whether the pSer7 peptide can compete
with the pSer5 peptide for binding to Ssu72 and thereby
inhibit its dephosphorylation. We included up to 20-fold
higher concentration of the pSer7 peptide (2mM) than the
pSer5 peptide (0.1 mM) in the assay but did not observe
any appreciable effect on the dephosphorylation of the
pSer5 peptide (results not shown). This supports our
structural observation that the affinity of Ssu72 for the
pSer5 peptide is substantially higher than that of the
pSer7 peptide.
Phosphorylation of CTD Tyr1 in yeast was recently
reported to inhibit the recruitment of Pol II termination
factors (Mayer et al. 2012). We tested the activity of Ssu72
toward a pSer7, pTyr1 doubly phosphorylated peptide, Ser2–
Pro3–Thr4–Ser5–Pro6–pSer7–pTyr19–Ser29–Pro39–Thr49–
Ser59, and found that Tyr1 phosphorylation had essentially
no effect on pSer7 dephosphorylation even though pTyr1
directly follows pSer7 in the primary sequence. This is
Figure 2. Ssu72 prefers pSer5 in the active site. (A) Omit 2Fo ! Fc
electron density for the CTD peptide phosphorylated at Ser2, Ser5,
and Ser7 at 2.0 A˚ resolution, contoured at 1s. There is no indication
of the binding of pSer7 into the catalytic site. (B) Overlay of the
active site region of Ssu72 in the triply phosphorylated peptide
complex (yellow) and the pSer5 complex (in gray) (Xiang et al. 2010).
A novel mode of Pol II CTD recognition






consistent with our structural observations that the Tyr1
side chain has weak electron density (Fig. 1B) and does not
make contact with Ssu72 (Fig. 1D).
We also used the entire Pol II CTD, purified as a GST
fusion protein and phosphorylated with purified Cdk7
(Akhtar et al. 2009; Glover-Cutter et al. 2009), as the
substrate in our assays. With this longer substrate and
using antibodies capable of recognizing pSer7 and pSer5
in Western blots to monitor dephosphorylation, Ssu72
demonstrated comparable activity toward pSer7 and
pSer5 (Fig. 3B), consistent with results reported earlier
(Bataille et al. 2012; Zhang et al. 2012). Moreover, the
symplekin NTD stimulated the pSer7 phosphatase activ-
ity of Ssu72 (Fig. 3C), as observed earlier with the pSer5
phosphatase activity (Xiang et al. 2010). We also found
that the prolyl isomerase Pin1 modestly (about twofold
based on reactivity with the anti-pSer7 antibody) (see the
Materials and Methods) stimulated dephosphorylation
of pSer7 in this GST-CTD substrate (Fig. 3D), consistent
with an earlier study in yeast cells (Bataille et al. 2012).
This apparent weak stimulation may reflect an indirect
effect by which Pin1 promotes dephosphorylation of pSer5,
which in turn makes pSer7 more accessible for dephos-
phorylation by Ssu72. Similar to results with the peptide
substrates, Fcp1 showed stronger activity toward both
pSer7 and pSer5 with the GST-CTD substrate than did
Ssu72 (Fig. 3B). The possible significance of this remains
to be determined.
The weak phosphatase activity of Ssu72 toward the
pSer7 peptide substrate is consistent with our structural
observations. The active site of Ssu72 likely has a higher
affinity for the CTD phosphorylated on Ser5, with the
pSer5–Pro6 peptide bond in the cis configuration. In the
presence of pSer5, the enzyme appears not to bind pSer7
in the active site. In addition, the Asp143 general acid is
misaligned in the pSer7 peptide complex, which would
further reduce the activity of Ssu72 toward this substrate.
On the other hand, with the full-length Pol II CTD sub-
strate, Ssu72 appears to have similar activity toward both
pSer5 and pSer7 (Bataille et al. 2012; Zhang et al. 2012). It
might be possible that other regions of the CTD can
indirectly affect the binding and/or catalysis of pSer7 in
the Ssu72 active site. It is also notable that activity to-
ward both pSer5 and pSer7, in the context of the intact
CTD, was strongly enhanced by the symplekin NTD.
This is consistent with the known requirement of this
interaction for Ssu72 function in yeast (Ghazy et al. 2009)
and may help to ensure that Ssu72 activity is constrained
until the appropriate time during the transcription cycle.
Overall, our results demonstrate a novel mode of sub-
strate recognition by Ssu72 and explain how the enzyme
can dephosphorylate both pSer5 and pSer7.
Materials and methods
Protein expression, purification, and crystallization
The experimental protocols followed those described earlier (Xiang et al.
2010). Briefly, human symplekinNTD and human Ssu72, both His-tagged,
were expressed in Escherichia coli and purified separately using nickel
affinity and gel filtration chromatography. The symplekin NTD–Ssu72
complex was purified by gel filtration after mixing the two proteins.
Crystals of this binary complex were transferred to a soaking solution
containing 100 mM Tris (pH 8.5), 10 mMNaCl, 25% (w/v) PEG 3000, and
either the pSer7 peptide (10 mM) for 48 h or the pSer2, pSer5, and pSer7
triply phosphorylated peptide (30 mM) for 16 h. The crystals were then
transferred to the same soaking solution supplemented with 25% (v/v)
ethylene glycol for 30 sec and flash-frozen in liquid nitrogen.
His-tagged yeast Fcp1 (168-606) was overexpressed in E. coli BL21 (DE3)
Star cells and purified by nickel affinity and gel filtration chromatography,
following a published protocol (Kamenski et al. 2004).
Data collection and structure determination
X-ray diffraction data were collected on an ADSC charge-coupled device at
the X29A beamline of National Synchrotron Light Source (NSLS). The
diffraction images were processed and scaled with the HKL package
(Otwinowski and Minor 1997). The structure refinement was carried
out with the program Refmac (Murshudov et al. 1997), and manual
rebuilding of the model was performed with the program Coot (Emsley
and Cowtan 2004). The statistics on the structure refinement are summa-
rized in Table 1.
Figure 3. Phosphatase activity of Ssu72 toward pSer5 and pSer7
substrates. (A) Relative phosphatase activity for human Ssu72 (black
bars) and yeast Fcp1 (gray bars) toward the pSer5 and pSer7 CTD
peptide substrates. The amount of phosphate released in each
reaction is normalized by the reaction time, substrate concentration,
and enzyme concentration. The activity for Ssu72 with the pSer7
substrate is set at 1. The vertical axis is shown in log scale. (B)
Phosphatase activity for human Ssu72 and yeast Fcp1 toward the
GST-CTD substrate phosphorylated with Cdk7. (C) Symplekin NTD
stimulates Ssu72 phosphatase activity toward both pSer7 and pSer5.
(D) The prolyl isomerase Pin1 stimulates Ssu72 phosphatase activity
toward pSer7 and pSer5 in the GST-CTD substrate.
Xiang et al.






CTD peptide phosphatase assays
Reaction mixtures (25 mL) containing 50 mM HEPES (pH 7.0), 100 mM
NaCl, 10 mMMgCl2, 500 mM to 2mMCTD peptide, and 5 mM to 200 mM
Ssu72 were incubated for 45 min (for pSer5 peptide) or 12 h (for pSer7
peptide) at room temperature and then quenched by adding 0.5 mL of
malachite green reagent (BIOMOL Research Laboratories). Assays with
Fcp1 were performed similarly, using 5 mM Fcp1 and 500 mM peptides.
Phosphate release was determined by measuring A620 and comparing it
with a phosphate standard curve.
GST-CTD phosphatase assays
Purified GST-CTD fusion protein was phosphorylated in vitro by Cdk7
complex as described (Glover-Cutter et al. 2009). CTD phosphatase assays
were performed in a total volume of 20 mL under the standard phosphatase
condition (50 mM Bis-Tris at pH 6.5, 20 mM KCl, 10 mM MgCl2, 5 mM
DTT) containing 200 ng of phosphorylated GST-CTD and the indicated
amount of Ssu72 or Fcp1. Reaction mixtures were incubated for 1 h at
30°C and stopped by adding 5 mL of 53 SDS loading buffer, and 2.5 mL from
each reaction was resolved on an 8% SDS-PAGE gel. pSer7 levels were
detected by Western blot using the 4E12 antibody (Millipore), and pSer5
levels were detected using the H14 antibody (Covance).
Pin1 stimulation assay
GST-Pin1 was prepared as previously described (Xiang et al. 2010). A 35-mL
reaction containing 100 mM Ssu72 with or without 200 nM GST-Pin1
was incubated at 10°C. Eight microliters was taken out at the indicated
time points, mixed with 2 mL of 53 SDS sample buffer, and boiled for 5
min. Two microliters was resolved in an 8% SDS-PAGE gel. pSer5 and
pSer7 levels were detected by Western blot with 3E8 (Millipore) and
4E12 antibodies, respectively, and quantitated with LI-COR. The same
experiment was also performed at room temperature, with similar
results.
pSer7 peptide inhibition of pSer5 peptide dephosphorylation
Ssu72 (10 mM) was preincubated with 0, 100 mM, 200 mM, 500 mM, 1mM,
or 2mMpSer7 CTD peptide in a buffer containing 50mMHEPES (pH 7.0),
100 mMNaCl, and 20 mMMgCl2 for 5 min at room temperature. A final
concentration of 100 mM pSer5 CTD peptide was added in each reaction.
The reaction was incubated for 45 min at 37°C and stopped by adding
malachite green reagent. After another 30 min, OD620 was recorded for
each reaction to determine phosphatase release.
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The activity of RNA polymerase II (Pol II) is controlled in part by the phosphorylation state 
of the C-terminal domain (CTD) of its largest subunit. Recent reports have suggested that 
yeast regulator of transcription protein, Rtr1, and its human homologue RPAP2, possess Pol 
II CTD Ser5 phosphatase activity. Here we report the crystal structure of Kluyveromyces lactis 
Rtr1, which reveals a new type of zinc finger protein and does not have any close structural 
homologues. Importantly, the structure does not show evidence of an active site, and extensive 
experiments to demonstrate its CTD phosphatase activity have been unsuccessful, suggesting 
that Rtr1 has a non-catalytic role in CTD dephosphorylation. 
1 Department of Biological Sciences, Columbia University, New York, 10027, USA. Correspondence and requests for materials should be addressed to L.T. 
(email: ltong@columbia.edu). 
The yeast regulator of transcription protein Rtr1 
lacks an active site and phosphatase activity
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The activity of RNA polymeraes II (Pol II) is regulated by the phosphorylation state of the C-terminal domain (CTD) of its largest subunit1–5, which contains the consensus heptapep-
tide repeat Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 (YSPTSPS). While 
all the hydroxyl groups in this repeat can become phosphorylated, 
phosphorylation of Ser2 and Ser5 has received the most attention 
to date. For example, phosphorylated Ser5 (pSer5) is found at the 
promoter and during the initiation and early stages of Pol II tran-
scription, and it mediates the recruitment of the 5`-end capping 
machinery and other factors. pSer5 is then dephosphorylated, and 
Ser2 becomes phosphorylated during the elongation and termina-
tion stages of transcription, which also facilitates 3`-end processing 
of the pre-mRNA transcript.
In keeping with the importance of Ser2 and Ser5 phosphoryla-
tion, the kinases and phosphatases involved have been well studied5. 
The phosphatase Fcp1 is present along the length of transcribed 
genes, and can dephosphorylate both pSer2 and pSer5, but prefers 
pSer26,7. Ssu72 is a known CTD pSer5 phosphatase8,9, although it 
is localized primarily near the 3`-end of genes. Ssu72 prefers the cis 
configuration of the pSer5-Pro6 peptide bond10,11, and it helps to 
couple transcription and polyadenylation10. Scp1 is another pSer5 
phosphatase in metazoans, and it may function near the 5` end of 
certain genes12–14.
It was recently reported that the yeast protein Rtr1 (regulator 
of transcription15) has Pol II CTD pSer5 phosphatase activity 
and is required for pSer5 dephosphorylation in the early stage 
of transcription16. The human homologue of Rtr1, RPAP2 (RNA 
Pol II-associated protein 217), has also been reported to have 
CTD pSer5 phosphatase activity18. These proteins are poorly con-
served overall (Fig. 1), but they share a motif with three strictly 
conserved Cys residues and another residue conserved as His 
(in most fungi) or Cys (in animals and S. pombe, Fig. 1), suggestive 
of a zinc finger motif15. However, the spacing among these residues 
(C-X4-C-Xn-C-X3-H/C, where n ranges from 30 to 50) as well as the 
sequences of Rtr1 homologues are distinct from known zinc finger 
proteins.
In this study, we report the crystal structure of Rtr1. It reveals a 
new type of zinc finger protein, in fact distinct from other known 
protein structures in general. However, the structure lacks an appar-
ent active site, and the zinc ion probably has a structural role, likely 
stabilizing the overall structure of the protein. Moreover, extensive 
efforts to demonstrate CTD phosphatase activity for Rtr1 from 
several different fungal species as well as for human RPAP2 were 
unsuccessful, in contrast to the earlier reports but consistent with 
the structural observations. Therefore, Rtr1/RPAP2 itself is unlikely 
a phosphatase, but perhaps has a non-catalytic role in CTD dephos-
phorylation. The identity of the pSer5 phosphatase in the early stage 
of Pol II transcription remains to be determined.
Results
Overall structure of Rtr1. We have determined the crystal 
structure of Kluyveromyces lactis Rtr1 (KlRtr1) at 2.5 Å resolution 
(Table 1, Supplementary Fig. S1). The bacterial growth media was 
supplemented with zinc during protein expression, and the purified 
protein had nearly stoichiometric amounts of zinc19. Fluorescence 
scans were carried out on the crystal at the absorption edges of Zn, 
Ni, Co and Fe, and anomalous signals were observed only at the Zn 
edge, which were used to solve the structure. The full-length protein 
(residues 1–211) was used for crystallization, but only residues 
1–152 were observed in the structure. SDS gels of the crystals 
showed that the C-terminal segment of KlRtr1 was removed by 
proteolysis during crystallization (Supplementary Fig. S2). The 
sequence conservation for these C-terminal residues is much weaker 
among Rtr1 and RPAP2 homologues (Fig. 1).
The structure of KlRtr1 (residues 1–152) contains five anti- 
parallel A-helices (AA–AE, Fig. 2a). A long loop (residues 70–112) 
connects helices AD and AE, and the three strictly conserved Cys 
residues (73, 78 and 111) are located in this loop. Residues 88–100 at 
the tip of this loop are disordered in the current structure (Fig. 2a), 
and this loop may have also been proteolysed in some of the Rtr1 
molecules in the crystal (Supplementary Fig. S2). The fourth ligand 
to the zinc ion, His115 or Cys, is in the first turn of helix AE. This 
helix is followed by another long loop (residues 126–152) that wraps 
around one side of the structure (Fig. 2a).
We also obtained crystals of Ashbya gossypii Rtr1 (AgRtr1), 
although the best diffraction data set extended only to 3.5 Å reso-
lution. By combining the structural information from KlRtr1 and 
primary phase information from Zn anomalous signals, we were 
able to observe another helix in the C-terminal region of AgRtr1, 
likely equivalent to residues 154–166 of KlRtr1 (Fig. 1). This helix 
is projected away from the rest of the protein and is stabilized by 
crystal packing interactions in the AgRtr1 crystal (Supplementary 
Fig. S3), suggesting that the C-terminal region of Rtr1 may function 
independently of the N-terminal region.
Rtr1 is a new type of zinc finger protein. The zinc ion is coordi-
nated in a tetrahedral fashion by the four conserved ligands (Fig. 2a 
and b). The zinc-binding site is located near the surface, but there 
are no prominent features in this region of the protein (see below). 
The main-chain carbonyl oxygen atoms of the first two ligands, 
S. S.               A B C D
KlRtr1     1  MATIEEIKEVVLKPYTNHRQLTIREVETISINLIDLLITKDVKDARTMKYISRFLTKQDYADLVQERNLVKRCGYPLCSKSQ
ScRtr1     1  MATIEDIKETALIPFQKHRQLSMHEAEVITLEIIGLLCDSECKDEKTLKYLGRFLTPDMYQDLVDERNLNKRCGYPLCGKSP
AgRtr1     1  MATIEDIQKQVLVAYQQHRQLSLKEADLLTVELLELLSQTECTP-ETLKYVGRFFTKTTYSDLIDERNLNKLCGYPLCGQSQ
HsRPAP2   29  TSTLKQEDASKRKAELEAAVRKKIEFERKALHIVEQLLEENITEEFLMECG-RFITPAHYSDVVDERSIVKLCGYPLCQKKL
S. S.                                               E
KlRtr1    83  ARVR-Dpfadvqmtn-flrQNNPYAYLTEYCTKAHFRCSQFYQFQLSDEALFARVGVHL------DDYEPPSEIQLLEevl
ScRtr1    83  ERIR-DPFSMNDTTKKFLLENNPYAYLSHYCSKFHFRCSQFYQVQLSDEALFARTGVHLFEDPEQDKHDIDFKVTLFEELL
AgRtr1    82  GRIR-DPYENRRVSN-FLTQNNPYKYLTSFCSKLHFRCSQFYQVQLSDEALFARVGVHL-------DDYEAGRVLLLEEAM
HsRPAP2  110  GIVPKQKYKISTKTN----KVYDITERKSFCSNFCYQASKFFEAQIPKTPVWVREEERH-----------PDFQLLKEEQS
S. S. F
.         .         .         .         .         .         .         .
.          .         .         .         .               .         .
.         .          .             .         .       .
KlRtr1   156  ---aresdvkqmirgmtdlkladdd-sre----emerdisdmladikiveinepniigdlgrdr 211
ScRtr1   163  REKASEEDIKSLISGLKKLGLNPDSGTTEKDDTELEDDLSKWLAQIKIVENDNPSILGDFTRED   226
AgRtr1   154  ---AEERDLRTMIRGMNGLSLGENG-AGD----ELQKDLSEWLSEVRIVENERPPLLGDLMKE    208
HsRPAP2  176  GHSGEEVQLCSKAIKTSDIDNPSHFEKQYESSSSSTHSDSSSDNEQDFVSSILPGNRPNSTNIRP  240 (612)
Figure 1 | Sequence conservation among Rtr1 and RPAP2 homologues. Sequence alignment of full-length K. lactis, S. cerevisiae and A. gossypii Rtr1 (KlRtr1, 
ScRtr1, AgRtr1) and human RPAP2 (HsRPAP2, residues 1–240 only, out of 612 residues total) is shown. The four zinc ligand residues are shown in orange. 
Residues conserved among 11 fungal Rtr1 homologues (excluding the second Rtr1 homolog in S. cerevisiae) or 8 animal RPAP2 homologues are shown in 
magenta. Residues conserved among fungal Rtr1 and animal RPAP2 homologues are shown in blue. Residues not observed in the crystal structure of KlRtr1 
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Cys73 and Cys78, are hydrogen bonded to the guanidinium group 
of Arg67, one of the few other conserved residues among these pro-
teins (Fig. 1). The hydrogen bonds stabilize the two Cys residues as 
well as the loop connecting them, which is hydrophobic in nature 
and contributes to the formation of the hydrophobic core of Rtr1 
(Fig. 2a). The zinc ion therefore seems to have a structural role, 
likely stabilizing the overall conformation of Rtr1.
We have identified Rtr1 as a new type of zinc finger protein. A 
search through the Protein Data Bank with DaliLite20 did not iden-
tify any close structural homologues, with the highest Z score being 
3.3. The overall fold of Rtr1 is somewhat reminiscent of the HEAT 
repeats, although the positions of the helices are different compared 
with these repeats. The topology of the zinc ligands in Rtr1, with the 
first three located in loops and the last one in the beginning of a helix, 
has some similarity to the A20 family of zinc finger proteins21, as 
illustrated by the structure of Rabex-5, a guanine nucleotide exchange 
factor for Rab5 that also binds monoubiquitin22,23. The overall con-
formations of the protein backbone near the first two zinc ligands 
are similar between Rtr1 and Rabex-5 (Fig. 2c). On the other hand, 
the loop connecting them, and especially the loop connecting to the 
third ligand, has different numbers of residues (the zinc ligands in 
Rabex-5 have the motif C-X3-C-X11-C-X2-C). In addition, the ori-
entation of the helix containing the fourth ligand differs by nearly 
90° between the two structures. Finally, the zinc-binding site in Rtr1 
is part of a much larger structure, with 150 residues (Fig. 2a), whereas 
the zinc finger domain of Rabex-5 contains only 35 residues.
Purified Rtr1/RPAP2 lack detectable CTD phosphatase activity. 
We next attempted to demonstrate Pol II CTD pSer5 phosphatase 
activity with our purified protein samples of His-tagged Rtr1 from 
K. lactis, A. gossypii, S. cerevisiae and several other fungal species. 
To test the possibility that Rtr1 in the absence of zinc or in complex 
with a different metal ion could be catalytically active, we used pro-
tein samples purified from E. coli cells that were grown without addi-
tional zinc in the medium. The zinc occupancy ranged between 10 
and 80%, but other metal ions could be present in these samples. We 
also expressed and purified residues 1–332 of human RPAP2, as His-
tagged and GST-fusion proteins, and full-length RPAP2 as a GST-
fusion protein18. Despite extensive efforts and using a large collection 
of different substrates (Supplementary Table S1), we failed to detect 
CTD pSer5 phosphatase activity for Rtr1 and RPAP2 under any of 
the conditions tested, while robust activity was observed with Ssu72. 
The substrates used include a CTD peptide Ser7``-Tyr1-Ser2-Pro3-
Thr4-Ser5-Pro6-Ser7-Tyr1`-Ser2` phosphorylated at the Ser5, Ser5 
and Ser7, or Ser2, Ser5 and Ser7 positions, as it has been shown that 
RPAP2 requires Ser7 phosphorylation to interact with the CTD18. 
These assays monitored the release of free phosphate from the reac-
tions. We also used as the substrate the entire CTD purified as a GST-
fusion protein10 and either phosphorylated with HeLa cell nuclear 
extract or purified Cdk7. The reactions were monitored by western 
blotting with an antibody specific for pSer5. We again failed to detect 
activity with multiple Rtr1/RPAP2 samples and under a variety of 
conditions (Fig. 3a and b and results not shown). In addition, we 
soaked Rtr1 crystals with CTD phosphopeptides, but were not able 
to identify any binding based on the crystallographic analysis.
The structure of Rtr1 lacks an apparent active site. The lack of 
phosphatase activity for Rtr1 is consistent with our structure, which 
Table 1 | Summary of crystallographic information.
K. lactis Rtr1 A. gossypii Rtr1
Data collection
 Space group P212121 I422
 Cell dimensions
  a, b, c (Å) 45.2, 88.7, 94.9 115.4, 115.4, 125.4
  A, B, G (°) 90, 90, 90 90, 90, 90
Peak Inflection Remote Peak
 Wavelength (Å) 1.2833 1.2836 1.2652 1.2830
 Resolution range (Å)* 50–2.5 (2.6–2.5) 50–2.5 (2.6–2.5) 50–2.5 (2.6–2.5) 50–3.5 (3.6–3.5)
 Rmerge (%) 5.5 (35.5) 5.6 (42.5) 5.6 (37.9) 6.5 (43.3)
 I/SI 21.9 (4.0) 21.3 (3.5) 21.1 (3.5) 18.4 (2.4)
 Completeness (%) 99 (100) 99 (100) 99 (99) 99 (100)
 Redundancy 3.7 (3.8) 3.7 (3.8) 3.7 (3.6) 4.4 (4.7)
Refinement
 Resolution (Å) 50–2.5
 No. of reflections 12,890
 Rwork/Rfree (%) 22.2/27.2
 No. of atoms
  Protein 2,243
  Ligand/ion 2
  Water 32
 B-factors
  Protein 57.9
  Ligand/ion 75.6
  Water 55.5
 R.m.s. deviations
  Bond lengths (Å) 0.017
  Bond angles (°) 1.6
Abbreviations: MAD, multiple-wavelength anomalous diffraction; R.m.s. deviation, root-mean-square deviation; SAD, single-wavelength anomalous diffraction.
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does not indicate the presence of an active site. An analysis of 
the surface features that are conserved among Rtr1 and RPAP2 
homologues does not reveal any pockets that are lined with 
conserved residues and could function as an active site (Fig. 4). 
The C-terminal segment that is missing in the current structure 
is unlikely to form an active site, owing to its poor conservation 
(Fig. 1). The zinc-binding site cannot be an active site either, as the 
zinc ion is tetrahedrally coordinated by the four ligands and is not 
capable of binding and activating a water molecule for hydrolytic 
activity. Moreover, the zinc-binding site corresponds to a small pro-
trusion on the surface of Rtr1 (Fig. 4), and there is no pocket nearby 
that could bind the CTD substrate. Mutation of one of the Zn 
ligands in ScRtr1 (Cys73) was reported to abolish the dephospho-
rylation of pSer5 in yeast cells16. It is more likely that this muta-
tion disrupted zinc binding and thereby the overall structure of the 
protein. We do not know why phosphatase activity was observed 
in vitro in the earlier reports16,18. A co-purifying protein with this 
activity might be a possibility.
Discussion
If Rtr1/RPAP2 is not a phosphatase, what then is its function in 
Pol II transcription? Rtr1 is found primarily in the cytoplasm, but 
can shuttle into the nucleus15. Recent reports suggest that Rtr1 and 
RPAP2 may have an important role in the assembly and transport of 
Pol II from the cytoplasm into the nucleus24–26. These and other15–18 
data establish that Rtr1 interacts with Pol II, and therefore it is likely 
that Rtr1 could mediate interactions among various proteins in the 
Pol II complex. Given the evidence that Rtr1/RPAP2 is important 
for pSer5 dephosphorylation in vivo16,18, an attractive possibility 
is that Rtr1/RPAP2 is required for recruitment and/or activation 
of the actual phosphatase that dephosphorylates pSer5 during the 
early stages of Pol II transcription. The identity of that phosphatase 
remains to be determined.
Methods
Protein expression and purification. Full-length Rtr1 from K. lactis, A. gossypii, 
S. cerevisiae and the N-terminal region (residues 1–332) of human RPAP2 were 
cloned into the pET28a vector (Novagen) and overexpressed in E. coli BL21 (DE3) 
Star cells at 20 °C by the addition of 0.5 mM isopropyl-B-d-thiogalactopyranoside 
at OD600 of 0.6. To help the zinc enrichment in the protein, 0.1 mM ZnSO4 was 
added to the culture 1 h before induction. The expression constructs introduced 
hexa-histidine tags at the N terminus of the proteins.
The soluble proteins were purified by Ni-NTA (Qiagen) with the elution buffer 
containing 20 mM Tris (pH 7.5), 200 mM NaCl and 250 mM imidazole, followed 
by gel filtration (Sephacryl S-300, GE Healthcare) chromatography in a running 
buffer of 20 mM Tris (pH 7.5), 200 mM NaCl and 2 mM DTT. The proteins were 
concentrated to 20 mg ml − 1 in a buffer containing 20 mM Tris (pH 7.5), 200 mM 
NaCl, 2 mM DTT and 5% (v/v) glycerol, flash frozen in liquid nitrogen and stored 
at  − 80 °C.
The GST fusion RPAP2 proteins were made by cloning the full-length human 
RPAP2 or the N-terminal region (residues 1–332) into pGEX-4T-3 (GE Life 
Sciences) vector and overexpressed in E. coli BL21 (DE3) Star cells with the same 
protocol as mentioned above. The proteins were purified by glutathione Sepharose 
4 Fast Flow (GE Healthcare) with 20 mM reduced glutathione in a buffer of 20 mM 
Tris (pH 7.5), 200 mM NaCl and 5% (v/v) glycerol.
Protein crystallization. Crystals of KlRtr1 were obtained with the sitting-drop 
vapour diffusion method at 20 °C. The reservoir solution contained 100 mM CHES 
(pH 9.5) and 20% (w/v) PEG8000. The crystals belong to space group P212121, and 
there are two molecules in the asymmetric unit. Crystals of AgRtr1 were obtained 
with the sitting-drop vapour diffusion method at 20 °C. The reservoir contained 
120 mM Tris (pH 7.0) and 16% (v/v) ethanol. The crystals belong to space group 
I422, and there is one molecule in the asymmetric unit. The crystals were cryo- 
protected by the respective reservoir solutions supplemented with 25% (v/v)  
ethylene glycol and flash frozen in liquid nitrogen for data collection at 100 K.
Data collection and structure determination. X-ray diffraction data were  





































Figure 2 | Rtr1 is a new type of zinc finger protein. (a) Schematic drawing 
of the structure of K. lactis Rtr1. The zinc atom is shown as a sphere (in 
orange), and its four ligands are shown as stick models (in cyan). The  
two views are related by a rotation of ~60° around the vertical axis.  
(b) Simulated annealing omit Fo–Fc electron density for the zinc atom  
and its ligands in the structure of KlRtr1 at 2.5 Å resolution, contoured at 
2.5S. (c) Overlay of the zinc-binding site of K. lactis Rtr1 (in colour) and the 
zinc finger domain of Rabex-5 (in grey). The superposition is based on the 
































































Figure 3 | Rtr1 and RPAP2 failed to show phosphatase activity with GST–
CTD as the substrate. (a) With the GST–CTD substrate phosphorylated 
by HeLa cell nuclear extract, KlRtr1 shows no signs of activity under various 
conditions. (b) Phosphatase activity of Rtr1 from different species and 
human RPAP2 was tested against GST–CTD substrate phosphorylated by 
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Synchrotron Light Source (NSLS). The diffraction images were processed and 
scaled with the HKL package27. The atomic coordinates of the KlRtr1 structure 
have been deposited in the Protein Data Bank under the accession code 4FC8.
Multiple-wavelength anomalous diffraction data sets were collected on the 
KlRtr1 crystal to 2.5 Å resolution, at the zinc absorption edge (inflection point, 
1.2836 Å), peak (1.2833 Å) and remote (1.2652 Å) wavelengths. The data processing 
statistics are summarized in Table 1. The Zn sites were located with the program 
BnP28. Reflection phases were calculated using the program SOLVE/RESOLVE29. 
The complete atomic model was fit into the electron density with the programs O30 
and Coot31. The structure refinement was carried out with the programs CNS32 
and Refmac33, against the data set at the peak wavelength. The statistics on the 
structure refinement are summarized in Table 1. For the final atomic model,  
95.2% of the residues are in the most favoured region of the Ramachandran plot, 
4.8% in additional allowed regions and none in the disallowed region.
For the AgRtr1 crystal, a single-wavelength anomalous diffraction data set to 
3.5 Å resolution was collected at the zinc peak wavelength. An electron density map 
was obtained based on the single-wavelength anomalous diffraction data, which 
showed clear indications for several helices. The atomic model of KlRtr1 could 
be readily positioned into the density, revealing an extra helix in the C-terminal 
region in the AgRtr1 structure. Refinement of this structure model was not carried 
out due to the limited resolution.
CTD peptide phosphatase assays. Reaction mixtures (25 Ml) in the standard 
phosphatase condition (50 mM Bis-Tris (pH 6.5), 20 mM KCl, 10 mM MgCl2  
and 5 mM DTT) containing 500 MM CTD peptide, Rtr1, RPAP2 or Ssu72 at  
1 MM, 5 MM or 20 MM concentration were incubated at 30 °C. Time-point  
samples were taken and quenched by adding 0.5 ml of malachite green reagent 
(BIOMOL Research Laboratories, Plymouth Meeting, PA). Phosphate release  
was determined by measuring A620 and comparing it with a phosphate  
standard curve.
CTD phosphatase assay. Purified GST–CTD fusion protein was phosphorylated  
in vitro by HeLa cell nuclear extract as described34, or by Cdk7 complex as  
described35. CTD phosphatase assays were performed in a total volume of  
20 Ml in the standard phosphatase condition containing 200 ng phosphorylated 
GST–CTD and indicated amount of Rtr1, RPAP2 or Ssu72. Reactions were  
incubated for 1 h at 30 °C, stopped by adding 5 Ml 5× SDS loading buffer and  
2.5 Ml from each reaction was resolved on an 8% SDS–PAGE gel. pSer5 level  
was detected by western blot using H14 antibody (Covance).
All CTD peptide phosphatase assays and CTD phosphatase assays were  
additionally performed in different conditions by varying pH (5.5–8.5) or KCl  
concentration (20–500 mM) or additives (1–10 mM ZnCl2 or MnCl2 or MgCl2) 
based on the standard phosphatase condition. 
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Figure 4 | The structure of Rtr1 does not show evidence for an active 
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Supplementary Figure S1. A stereo view of the final 2Fo–Fc electron density map at 2.5 
















Supplementary Figure S2. An SDS gel of purified KlRtr1 and KlRtr1 crystals. 
Proteolysis during crystallization removed the C-terminal segment of KlRtr1. Proteolysis 
in the 87-101 region (αD-αE loop) may have also occurred in some of the KlRtr1 








Supplementary Figure S3. The C-terminal helix in the AgRtr1 structure is stabilized by 







Supplementary Table S1 Summary of attempted phosphatase assays 
 
Enzyme Substrates1 
CTD peptide with phosphates on Ser5, Ser5 and Ser7, 
or Ser2, Ser5 and Ser7 (peptides were produced by 
chemical synthesis) 
GST-CTD phosphorylated by HeLa cell nuclear extract 
Fungal Rtr1 (S. cerevisiae, K. 
lactis, A. gosspyii, V. polyspora, 
Z. rouxii, D. hansenii, C. 
glabrata), full-length proteins 
with His-tag GST-CTD phosphorylated by Cdk7 
  
GST-CTD phosphorylated by HeLa cell nuclear extract Human RPAP2 (residues 1-332), 
His-tagged or GST-fusion 
protein; full-length RPAP2, 
GST-fusion 
GST-CTD phosphorylated by Cdk7 
1
 Reactions with the peptide substrates were monitored using the BioMol reagent. 
Reactions with GST-CTD were monitored by Western blot with the H14 antibody.  
 
 
  
 
